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Survival for patients with osteosarcoma has not improved for > 30 years. Despite 
aggressive multi-agent chemotherapy combined with surgical resection, a significant 
fraction of patients with localized disease relapse after optimal treatment. We evaluated 
the occurrence of cytoplasmic LC3B (light chain 3B)-positive puncta (a marker of 
autophagy) and presence of HSP27 (heat shock protein 27) in cancer cells within pre-
treatment biopsy, post-treatment surgical resection, and metastatic osteosarcoma 
specimens by immunohistochemistry in 260 patients. LCB3+ puncta expression was seen 
in 34% of pre-treatment. 50% of resection, and 67% of metastasis samples. Sixty-six 
percent of all specimens were scored positive for HSP27 (85% of pre-treatment. 52% of 
resection, and 50% of metastasis samples). Among 215 patients with localized disease, 
pre-treatment HSP27 expression was associated with inferior overall survival (adjusted 
HR 26.7, p=0.0263) as well as at resection following chemotherapy (adjusted HR 1.85, 
p=0.039). Lack of LC3B-puncta expression was an independent poor prognostic marker 
at resection (adjusted HR 1.75, p=0.045). Patients with LC3B+/HSP27- tumors at 
resection had the best prognosis whereas patients with LC3B-/HSP27+ osteosarcoma had 
the worst long-term survival. Neither HSP27 nor LC3B expression correlated with tumor 
necrosis. These findings indicate that HSP27 expression is a negative prognostic 
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biomarker in osteosarcoma.  Conversely, presence of autophagy following neoadjuvant 
chemotherapy, as measured by LC3B-puncta, predicts longer overall survival in 
osteosarcoma patients with localized disease.  
We additionally evaluated the significance of chemotherapy-induced autophagy in 
2 human osteosarcoma cell lines: LM7 and CCH-OS-D. Both doxorubicin (DOX) and 
cisplatin (CDDP) were found to induce autophagy. In LM7 cells, autophagy inhibition 
with hydroxychloroquine (HCQ) prior to chemotherapy resulted in a trend towards 
decreased viability consistent with a cytoprotective role of autophagy. In CCH-OS-D 
cells, autophagy inhibition prior to DOX significantly decreased chemosensitivity 
suggesting a cytotoxic role of autophagy in this setting. The post-treatment expression of 
phosphorylated HSP27 was increased in LM7 and decreased in CCH-OS-D following 
DOX or CDDP. These findings support a dual role of chemotherapy-induced autophagy 
and potential application of pHSP27 as a predictive biomarker of autophagy inhibitors in 
osteosarcoma.   
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I. Background:  
Current Therapies for Osteosarcoma 
Bone sarcomas are rare, making up 0.2% of all cancers.1 Osteosarcoma is the 
most common bone sarcoma with approximately 1000 new cases per year in the U.S. and 
predominantly effects adolescents and young adults.2 Prior to the introduction of multi-
agent chemotherapy, survival for patients with osteosarcoma was extremely poor with 
long-term survival <20%.3 Up to 90% of patients developed metastatic disease following 
surgery alone, leading to the hypothesis that the majority of patients have subclinical 
micrometastatic disease at presentation. With the addition of perioperative chemotherapy 
beginning in the 1960s and 1970s, survival for patients with localized osteosarcoma has 
now improved to 60-65%.4 While chemotherapy plays an integral role in curative 
treatment for patients with osteosarcoma, chemotherapy alone is inadequate. Patients who 
do not undergo surgical resection of their disease will eventually relapse.5 These 
observations have informed the current treatment paradigm for osteosarcoma which 
consists of preoperative combination chemotherapy with MAP (cisplatin, doxorubicin, 
and high-dose methotrexate) followed by limb-sparing surgery (when feasible) with 
pathologic response assessment and subsequent MAP chemotherapy (Figure 1). Despite 
these advances, there is still a significant fraction of patients who relapse and die of 
pulmonary metastasis,6 and there have been no significant improvements in overall 
survival for >30 years.4, 7 
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Figure 1. Standard treatment schema for localized osteosarcoma. Tumor tissue is 
obtained prior to treatment, at resection, and at relapse (blue dots). 
The prognosis for patients with metastatic disease is particularly poor and 
treatment of recurrent/metastatic disease remains a challenge. Patients with primary 
metastatic disease (those presenting with overtly metastatic disease at diagnosis) have a 
5-year survival of approximately 30-50%8, 9 and those with metastatic recurrence have 
even lower 5-year survival of 15-20%.10 Pulmonary metastasectomy can be curative in 
patients with limited/resectable pulmonary disease whereas unresectable metastatic 
disease (such as multiple osseous metastases or extensive pulmonary disease) is likely 
incurable. While a number of chemotherapeutic regimens have been evaluated either 
retrospectively or in the context of clinical trials, response rates range from 10-40% with 
4-month progression-free survival rates ranging from 25 to > 45% (selected studies in 
Table 1). The pooled outcomes for patients with recurrent osteosarcoma enrolled on 7 
phase 2 clinical trials through the Children’s Oncology Group (COG) and its predecessor 
cooperative groups are even more discouraging.11 In each individual trial, the drugs tested 
were deemed to be inactive. The event-free survival (EFS) for patients with measurable 
disease was 12% at 4 months (95% CI, 6% - 19%) with no significant difference in EFS 
based upon patient demographics or the number of prior treatment regimens. For patients 
with pulmonary metastasis who were rendered disease free by surgery and were treated 
Pre-treatment	Biopsy	 Limb	Salvage		
Pathologic	Response	
Assessment	
(%	tumor	necrosis)	
Post-op	Chemotherapy	(MAP)		
Possible	Relapse/
Metastasis	
Pre-op	Chemotherapy	(MAP)	
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on study AOST0221 (inhaled GM-CSF), the EFS was significantly better than those with 
unresectable disease but remained low, 20% at 12 months (95% CI, 10-34%). Another 
recent study of advanced bone sarcoma patients treated in phase I clinical trials at MD 
Anderson Cancer Center re-demonstrated the overall poor outcomes and lack of effective 
therapies for these patients. This included pediatric and adult osteosarcoma patients 
treated across 14 unique protocols and showed no response to any of the cytotoxic, 
targeted, or biologic agents used.12 The 4-month progression-free survival (PFS) was 
26% for patients with recurrent osteosarcoma. 
 
Chemotherapy Regimen Outcome Study 
Gemcitabine + docetaxel PR: 3/10; SD 1/10 Navid F, et al. Cancer. 
2008.13 
Cyclophosphamide + 
etoposide 
PFS at 4 months: 42% Massimo B, et all. Cancer. 
2009.14 
Cyclophosphamide + 
topotecan 
PR: 2/18 Saylors RL, et al. JCO. 
2001.15 
Ifosfamide + etoposide PR or CR: 3/8 Miser JS, et al. JCO. 198716 
Ifosfamide + carboplatin + 
etoposide 
ORR: 51% (all sarcomas) Van Winkle P, et al. Pediatr 
Blood Cancer. 2005.17 
High-dose ifosfamide ORR 20% 
PFS at 4mo: 25% 
Palmarini E, et al. ASCO, 
2015.18 
Sorafenib + everolimus PFS at 6 mo: 45% Grignani G, et al Lancet 
Onc. 2015.19 
Table 1. Treatment outcomes for relapsed/metastatic osteosarcoma. Complete response 
(CR), objective response rate (ORR), progression-free survival (PFS), partial response 
(PR), stable disease (SD). 
Given the adverse outcomes and limited efficacy of treatment in the 
recurrent/metastatic setting as well as the lack of promising agents in early-phase 
development, it is important to identify patients with a high-likelihood of metastatic 
relapse and death for consideration of clinical trial participation in studies that combine 
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molecular biomarkers and targeted therapies, either in the neoadjuvant or adjuvant 
setting, to improve the efficacy of standard chemotherapy for osteosarcoma. As such, the 
identification of novel prognostic biomarkers either at diagnosis or resection following 
neoadjuvant chemotherapy is an unmet need in osteosarcoma. 
 
Prognostic Markers in Osteosarcoma 
Due to the potential for relapse amongst patients treated with standard therapy, 
several studies have sought to identify prognostic markers in patients with osteosarcoma. 
To date, stage at presentation (localized vs metastatic) and pathologic response to 
neoadjuvant chemotherapy (assessed by percent necrosis at the time of surgical resection) 
remain the most widely accepted and clinically utilized prognostic factors. Other clinical 
and pathologic factors have been explored as they relate to metastasis-free and overall 
survival including age at diagnosis, sex, stage at presentation, tumor location, tumor size, 
histologic subtype, surgical margins, and serum markers such as lactate dehydrogenase 
(LDH) level or alkaline phosphatase levels among others.20-23 For example, in one large 
retrospective cohort of 1,702 patients with high-grade osteosarcoma treated on 
neoadjuvant cooperative group protocols, older patient age at diagnosis (≥ 40 years), 
axial tumor site, larger tumor size (for extremity tumors), and presence of primary 
metastasis were associated with inferior overall survival.21 Treatment-related factors 
including response to chemotherapy and the extent of surgery (incomplete vs 
macroscopically complete) were also shown to be significant. In multivariate analysis, 
residual tumor (HR 4.01, p< 0.0001) and poor response to chemotherapy (HR 2.44, p< 
0.0001) were identified as key prognostic factors for overall survival. 
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Identifying patients with localized (i.e. non-metastatic) disease that are at high-
risk for relapse is clinically relevant and has informed the design of adjuvant therapy 
trials in osteosarcoma. Pathologic response to chemotherapy, as assessed by percent 
tumor necrosis on the primary resection specimen, is a well-established prognostic factor 
in osteosarcoma.24 Poor response has been defined as <90% tumor necrosis in most 
studies, however this cutoff may vary. In early studies of preoperative chemotherapy, 
patients with a poor response to MAP chemotherapy had significantly worse outcomes.25, 
26 These findings were confirmed in an initial literature review of studies that included 
non-metastatic high-grade osteosarcoma patients published between 1973-1992 where 
only tumor necrosis following preoperative chemotherapy was found to have independent 
prognostic significance.27 In a subsequent systematic review including studies from 1992-
2006, poor response to chemotherapy (pooled relative risk (RR) of death or recurrence 
2.37, 95%CI 2.07-2.70), larger tumor volume (pooled RR 1.36, 95%CI 1.18-1.58) and 
ablative surgery as compared to limb salvage (pooled RR 2.18, 1.58-3.00) were all 
identified as predictors of adverse outcomes.28 However, the authors noted that a pooled 
analysis was challenging due the heterogeneity of the prognostic factors analyzed across 
studies.  
With the identification of tumor necrosis as a prognostic biomarker in 
osteosarcoma, multiple clinical trials have sought to intensify either preoperative 
chemotherapy to improve pathologic response rates or modify postoperative therapy to 
improve outcomes among poor responders. Intensification of preoperative therapy can 
result in higher rates of “good necrosis,” but this strategy results in greater toxicity 
without clear survival benefit. In a phase II study evaluating intensification of 
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preoperative chemotherapy, the addition of ifosfamide to a standard doxorubicin/cisplatin 
backbone with autologous stem cell rescue resulted in an improvement in the objective 
rate of tumor necrosis but resulted in unacceptable toxicity and no significant 
improvement in survival.29  
The role of tailored or modified post-operative therapy for patients with poor 
tumor necrosis remains controverted. The initial rationale for modification of 
postoperative chemotherapy amongst poor responders was established in the 1970s when 
primary (preoperative) therapy consisted of a less active drug combination than current 
MAP chemotherapy.26  In subsequent studies from the Rizzoli Institute, intensification of 
postoperative chemotherapy amongst poor responders improved survival: patients 
received neoadjuvant chemotherapy with 2 cycles of high-dose methotrexate (HD MTX), 
intra-arterial cisplatin, and intravenous doxorubicin followed by surgical resection; poor 
responders (<90% tumor necrosis) went on to receive additional chemotherapy with 
ifosfamide and etoposide (I/E) in addition to MAP.30 The 5-year continuous disease-free 
survival (CDFS) was 63%, with no significant difference between good and poor 
responders. These findings have informed the subsequent treatment paradigm for patients 
with poor response to MAP chemotherapy. In one large retrospective series of adult 
patients with osteosarcoma treated at MD Anderson Cancer Center, the addition of high-
dose ifosfamide to postoperative therapy increased the CDFS amongst poor responders to 
67%.31, 32 These findings were validated in an updated series of adult patients treated 
within the same center.33 A recent large international randomized clinical trial has called 
the utility of this approach into question, however. In the EURAMOS-01 study, 618 
patients with poor tumor necrosis following preoperative MAP chemotherapy were 
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randomized to receive either MAP or MAP plus ifosfamide and etoposide (MAPIE).34 
Toxicity was noted to be higher in the MAPIE group and EFS did not differ between 
treatment groups (HR 0.98, 95% CI 0.78 – 1.23), leading investigators to conclude that 
the results do not support the addition of I/E to postoperative therapy for patients with 
poor response and that “new strategies are required to improve outcomes in this setting.” 
Similarly, a retrospective analysis of assessing the prognostic value to histologic response 
to therapy between a historic regimen (CCG-78235) vs increased intensity induction 
therapy (INT-013336) found that while histologic response predicted outcomes across 
studies (p <0.0001), there was an inverse relationship between the predictive value of 
tumor necrosis and the intensity of induction therapy.37 Stated another way, the difference 
in outcomes between good and poor responders was less dramatic with modern 
intensified chemotherapy as compared to prior regimens (10y EFS 70.8% vs 58.4% in 
good v poor responders respectively in INT-0133 as compared to 75.4% vs 39.9% in 
CCG-782). Thus the authors concluded that their findings “highlight the need for novel 
markers” to develop treatment strategies in future trials. 
To date, there are no established predictive biomarkers of response to MAP 
chemotherapy in osteosarcoma. Identifying poor risk patients at diagnosis would allow 
for a window trial approach with correlative biomarkers. Similarly, additional factors that 
allow for risk stratification independent of tumor necrosis would be valuable in informing 
future studies of adjuvant therapy in osteosarcoma.  Therefore, research to identify novel 
biomarkers (both predictive and/or prognostic), potential targets focusing on mechanisms 
of chemoresistance, and opportunities to enhance efficacy/sensitivity to standard agents 
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(MAP) is imperative to inform clinical trial design and improve outcomes for patients 
with osteosarcoma. 
 
Autophagy in Cancer and Cancer Treatment 
Autophagy is a conserved physiologic process of cellular catabolism that allows 
the degradation and recycling of intracellular organelles, proteins, and macromolecules in 
order to maintain homeostasis during times of nutrient depravation and cellular stress.38 
The process of sequestering and breakdown of these cellular components through 
lysosoamal degradation is termed macroautophagy (referred to as autophagy henceforth). 
In this process, autophagy-related proteins sequester macromolecules to be degraded into 
double-membrane vesicles (termed autophagosomes). Autophagosomes fuse with the 
lysosome to form the autolysosome in which the macromolecules and organelles are then 
broken down into amino acids, nucleic acids, and fatty acids which can be used to 
maintain adenosine triphosphate (ATP) synthesis and support other key anabolic 
pathways. Macroautophagy has been the primary focus for studies of autophagy and 
autophagy inhibition in cancer. This differs from microautophagy (a nonselective 
lysosomal degradation by direct engulfment)39, chaperone-mediated autophagy (in which 
chaperones in the cytosol facilitate lysosomal proetolysis)38, and mitophagy (which refers 
to the degradation of mitochondria by autophagy).40  
Autophagy serves a dual role, either as a mechanism of cell survival or of cell 
death. As a cytoprotective mechanism, autophagy promotes cell survival in the setting of 
nutrient deprivation or other stress. Alternatively uncontrolled/excess autophagy can lead 
to cell death through apoptosis or an alternate cell death pathway termed “autophagic cell 
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death.” For example, studies have shown that knockdown of key autophagy (ATG) genes 
can promote both apoptotic and non-apoptotic cell death, suggesting that the role of 
autophagy is cytoprotective.39 Conversely, multiple lines of evidence support the 
rationale for autophagy as an alternate cell death pathway: 1) overexpression of 
autophagy proteins such as Beclin 1 or Atg1 can lead to cell death,41, 42 2) cells that are 
deficient in  apoptosis can undergo ATG-dependent cell death,43, 44 and 3) pharmacologic 
inhibition of autophagy may prevent cell death in certain settings.45, 46 This duality is 
particularly important in cancer and has implications for both carcinogenesis and cancer 
treatment. 
In cancer, the dual role of autophagy is often referred to as the “autophagy 
paradox.” In the early stage of tumorigenesis, autophagy has been shown to act as a 
tumor suppressor. Inhibition of autophagy through allelic deletion of Becn1 in genetic 
mouse models (BENC+/-) promotes tumorigenesis and results in a high incidence of 
spontaneous tumors.47, 48 Additionally, autophagy inhibition can lead to increased 
metabolic stress and genomic instability which can promote tumorigenesis and tumor 
progression.49 Conversely, activation and up regulation of autophagy is thought to 
contribute to tumor growth, tumor progression, and treatment resistance by promoting 
cell survival during periods of nutrient deprivation, chemotherapy, or radiation-induced 
stress.50 Because of this apparent paradox, there has been significant controversy 
regarding the role of autophagy modulation in cancer therapy.  
Autophagy markers such as LC3B puncta, p62/sequestosome 1 (SQSTM1), 
Beclin 1, and presence of autophagic vesicles or autophagosomes (evaluated by 
transmission electron microscopy [TEM]) have been explored as potential predictive and 
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prognostic biomarkers in multiple cancer types. For example, in a series of 12 patients 
with melanoma treated on a phase II trial of sorafenib and temozolimide, patients whose 
tumors had a high “autophagic index” (defined as ≥6 autophagic vesicles per cell on EM) 
were less likely to respond to treatment and had shorter survival as compared to those 
with a low autophagic index.51 In another series, the presence of high LC3 expression in 
pancreatic adenocarcinomas at time of pancreatoduodenectomy was associated inferior 
disease-free survival.52 In colon cancer, overexpression of Beclin 1 has been associated 
with inferior overall survival amongst patients receiving adjuvant 5-fluorouracil 
chemotherapy.53 While the presence of autophagy appears to be a negative prognostic 
marker in most cancer types, high expression of LC3 and Beclin 1 has been associated 
with improved response rate and superior overall survival in patients with ovarian 
cancer.54 In breast cancer, studies are conflicting. In one study, the presence of LC3B (but 
not Beclin 1) in residual tumors following neoadjuvant chemotherapy predicted inferior 
relapse-free survival (RFS; multivariate HR 1.88, 95% CI 1.14-3.08) and overall survival 
(OS; multivariate HR 2.43, 95% CI 1.26-4.67).55 A subsequent study found that when 
combined, the presence of LC3B+ puncta and nuclear HMGB1 expression in women 
with breast was associated with significantly improved metastasis-free survival following 
adjuvant chemotherapy (HR 0.49, 95% CI 0.26-0.89).56 Conflicting studies such as these, 
call into question the importance of evaluating autophagy in a context-dependent manner 
and additionally raise concerns about the methodology for evaluating autophagy markers 
in patient samples. As autophagy is a dynamic process, it is important to distinguish 
between static measurements of autophagy from those which measure autophagic flux. 
This has been a major limitation of prior studies. Expert guidelines recommend that the 
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use of autophagy markers such as  LC3B be accompanied by assays to estimate overall 
autophagic flux.57 In the study by Ladoire et al., the presence of cytoplasmic LC3B 
puncta was shown to have an inverse correlation with p62 staining, supporting the 
authors conclusion that in their study population high LC3B puncta reflects increased 
autophagic flux.56 No studies have evaluated the predictive or prognostic significance of 
autophagy markers in osteosarcoma. 
A wide range of current cancer drugs have been shown to modulate autophagy. 
For example, cytotoxic chemotherapies, hormonal therapies, and targeted therapies such 
as mTOR (mammalian target of rapamycin) inhibitors, HDAC (histone deacetylase) 
inhibitors, and multiple tyrosine kinase inhibiors (TKIs) have all been shown to induce 
autophagy in various cancer types.58  The listing of approved agents by the United States 
Food and Drug Administration (FDA) that inhibit autophagy is much shorter, including 
the antimalarial drugs chloroquine and hydroxychloroquine (HCQ) which inhibit 
lysosomal degradation. Several clinical trials have been conducted or are currently 
underway utilizing HCQ to inhibit autophagy.59 However, an important question remains: 
is autophagy inhibition beneficial or potentially detrimental?  
The role of autophagy in cancer is context-dependent and can vary based upon 
tumor type, stage (premalignant vs invasive), and cancer therapy.60 Recently studies have 
suggested that the role of autophagy and therefore the efficacy of autophagy inhibition 
may be dependent on p53 status. In a pancreas cancer genetically engineered mouse 
model (GEMM) of Kras-mutant, Trp53 -/- pancreatic adenocarcinoma, loss of autophagy 
via tumor specific Atg5 or Atg7 deletion or pharmacologic inhibition with 
hydroxycloroquine accelerated the development of pancreatic ductal adenocarcinomas.61 
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These findings called into question the safety of autophagy inhibition in patients with 
TP53-mutant cancers.62 Subsequent studies have refuted these findings based upon a 
pancreas-specific Kras-mutant Trp53+/− GEMM.63 This model allows for adult p53 loss 
of function via loss of heterozygosity (LOH) (rather than embryonic loss of p53) and is 
thought to more accurately recapitulate pancreatic tumor progression in humans. In this 
study, Atg5 deletion resulted in tumor suppression, with an increase premalignant lesions 
but preventing progression to pancreatic ductal adenocarcinoma and leading to prolonged 
survival. Taken together, these findings suggest that p53 status alone does not determine 
the role of autophagy in cancer. Rather, additional studies are needed to identify potential 
biomarkers that correlate with the role of autophagy in specific context (cancer type, 
therapy, stage) and may predict the therapeutic benefit of autophagy modulation. 
 
Autophagy in Osteosarcoma 
In osteosarcoma, most studies have focused on chemotherapy-induced autophagy 
as a mechanism of chemoresistance.64 Cisplatin, doxorubicin, and methotrexate have all 
been shown to induce autophagy in osteosarcoma cells, which then promotes tumor cell 
survival by decreasing sensitivity to chemotherapy.65-67 Autophagy inhibition, either via 
knockdown of key autophagy genes such as Beclin 168 or pharmacologic inhibition with 
compounds such as 3-methyladenine,67 bafilomycin A1,69 or chloroquine66 have been 
shown to decrease cell proliferation and increase apoptosis in osteosarcoma cells treated 
with doxorubicin or cisplatin. Further, MAP chemotherapy results in the upregulation of 
high mobility group box 1 protein (HMGB1) in osteosarcoma in vitro and has been 
suggested as a potential therapeutic target in osteosarcoma.70, 71  
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Our lab has previously shown a dual role for chemotherapy-induced autophagy in 
osteosarcoma.72, 73 Gemcitabine (GCB) treatment of human LM7, CCH-OS-D, and 
murine K7M3 cells in vitro and osteosarcoma lung metastases in vivo resulted in the 
formation of autophagic vesicles, conversion of LC3I to LC3II, and upregulation of 
Beclin 1 in both cells and tumor tissues as well as degradation of p62 and the formation 
of acidic vesicular organelles in tumor cells consistent with induction of autophagy. To 
evaluate the role of autophagy, we analyzed cell viability following treatment with 
chemotherapy combined with inhibition of autophagy by BECN1 or ATG knockdown and 
pharmacologic inhibition with hydroxychloroquine (HCQ).  In LM7, chemotherapy in 
combination with autophagy inhibition by BECN1 knockdown or HCQ treatment resulted 
in decreased viability suggesting a cytoprotective role for autophagy. Conversely, 
autophagy inhibition prior to chemotherapy resulted in increased cell viability of CCH-
OS-D and K7M3 cells consistent with cytotoxic autophagy.  
 
Phosphorylated HSP27 as a Potential Biomarker of Chemotherapy-induced 
Autophagy in Osteosarcoma 
We completed a human phosphokinase array to identify differentially expressed 
proteins and phosphoproteins at baseline and following treatment with GCB in 
osteosarcoma cell lines exhibiting opposing effects of autophagy and autophagy 
inhibition. Post-treatment expression of phosphorylated heat shock protein 27 (pHSP27) 
was significantly different between LM7 and CCH-OS-D cells following gemcitabine 
exposure and appeared to correlate with the role of chemotherapy-induced autophagy. 
Induction of pHSP27 following treatment with GCB correlated with a cytoprotective role 
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of autophagy and reduced chemosensitivity, while a failure to induce pHSP27 correlated 
with a cytotoxic role of autophagy. Inhibition of autophagy in cells with increased 
expression of pHSP27 following drug exposure resulted in increased osteosarcoma cell 
killing; conversely inhibition of autophagy in cells with decreased expression of pHSP27 
following treatment decreased osteosarcoma cell killing.73 These findings were validated 
in K7M3 cells treated with 9-nitrocamptothecin (9-NC). Previously, our lab has shown 
that inhibiting autophagy in K7M3 cells prior to treatment with 9-NC increases 
cytotoxicity whereas autophagy inhibition prior to treatment with GCB reduced 
cytotoxicity as compared to GCB alone.72 In a subsequent study, we found that this effect 
again correlated with the post-treatment expression of pHSP27: 9-NC resulted in 
induction of pHSP27 (and correlated with cytoprotective autophagy) whereas pHSP27 
was decreased following GCB treatment in K7M3 (correlating with cytotoxic 
autophagy). The correlation between pHSP27 expression and the role of chemotherapy-
induced autophagy in osteosarcoma was independent of cell line, species of origin, or 
specific chemotherapy (summarized in Table 2). Taken together, our findings suggest 
that pHSP27 may be a biomarker to predict the benefit of autophagy inhibitors in the 
treatment of osteosarcoma. 
 
Cell Line Chemotherapy pHSP27 expression Role of Autophagy 
LM7 GCB Increase Cell survival 
CCH-OS-D GCB Decrease Cell death 
K7M3 GCB Decrease Cell death 
K7M3 9-NC Increase Cell survival 
MG63 GCB No change No effect 
Table 2. Correlations between post-treatment expression of pHSP27 and the role of 
chemotherapy-induced autophagy in vitro. GCB – gemcitabine, 9-NC – 9-
nitrocamptothecin. 
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In the proposed model, treatment with chemotherapy in osteosarcoma results in an 
induction of autophagy. This can be accompanied by an increase in pHSP27 (Figure 2, a) 
which is associated with chemoresistance and cytoprotective autophagy or conversely, a 
degradation of pHSP27 associated with cytotoxic autophagy and autophagic cell death 
(b). In the first scenario, autophagy inhibition with drugs such as HCQ results in 
increased chemosensitivity (Figure 2, c). In the second, autophagy inhibition would result 
in decreased drug sensitivity (d). 
 
 
Figure 2. Proposed model for chemotherapy-induced autophagy and pHSP27 in 
osteosarcoma. (a) Increased pHSP27 expression following chemotherapy correlates with 
cytoprotective autophagy; (b) Decreased pHSP27 correlates with cytotoxic autophagy.  
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Figure 2 (continued). (c) Autophagy inhibition increases drug sensitivity (decreased cell 
viability). Viability studies show a decrease in LM7 viability with the combination of 
HCQ and GCB as compared to GCB alone; (d) Autophagy inhibition decreases drug 
sensitivity (increased cell viability) in osteosarcoma cells with decreased post-treatment 
pHSP27 expression. Viability studies show an increase in CCH-OS-D viability with the 
combination of HCQ and GCB as compared to GCB alone. Cell viability data reproduced 
with permission, courtesy Janice Santiago-O’Farrill PhD. 
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Heat shock Protein 27 (HSP27) in Cancer and Cancer Treatment 
Heat shock proteins (HSPs) are a highly conserved class of cytoprotective 
proteins whose synthesis is stimulated by heat shock (as their name implies) as well as 
other environmental and physiologic stressors. Heat shock protein 27 (also known as 
HSPB1) is a small HSP (molecular weight 27 kD) that is found in both normal cells and 
human cancers.74 Gene expression data from the Cancer Genome Atlas (TCGA) and the 
Genotype-Tissue Expression Project (GTEx)75 show that HSP27 is highly expressed 
across a range of normal tissues and tumor types including soft tissue sarcomas, with 
uterine and soft tissue leiomyosarcoma being most notable (Figure 3; ULMS and 
STLMS, respectively). Notably, osteosarcoma expression data is not included in the 
TCGA.  
 
 
Figure 3. HSP27 expression across normal tissues and multiple cancer subtypes. The 
results presented here are in part based upon data generated by the TCGA Research 
Network: http://cancergenome.nih.gov/. 
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In cancer, HSP27 expression can be induced by cytotoxic drugs and protects cells 
from apoptotic cell death. Overexpression of HSP27 is a poor prognostic biomarker in 
multiple cancers including gastric, liver, prostate, rectal and breast, and is additionally a 
marker of chemotherapy resistance in breast cancer and leukemia.76, 77 
HSP27 can undergo post-translational modification via serine phosphorylation; 
human HSP27 is phosphorylated at serine15, serine-78, and serine-82 by MAPKAP 
kinase 2/3 via the activation of the P38 MAPK pathway.78 Phosphorylation is a dynamic, 
reversible process that can affect structure, oligimerization, and function. Heat shock as 
well as other stressors have been shown to induce phosphorylation. Interestingly, early 
studies noted that agents such as tumor necrosis factor (TNF) and leukemia inhibitory 
factor only induced HSP27 phosphorylation in cells that were sensitive to the agents.74 
Similarly, in human breast cancer cells, phorbol ester induces HSP27 phosphorylation 
and inhibits cell growth.79 More recently, pHSP27 has been associated with gemcitabine-
resistance in pancreatic cancer cells as well as 5-fluorouracil resistance in colorectal 
cancer.80, 81 As a prognostic marker, pHSP27 expression is inversely correlated with 
tumor size and stage and was noted to decrease at progression in hepatocellular 
carcinoma82 and was shown to correlate with HER-2 status and node positivity in breast 
cancer.83  
While previously unactionable, several strategies are being developed to target 
heat shock proteins in cancer therapy.84 Recent studies with the novel HSP27 antisense 
oligonucleotide OGX-427 have shown promise in multiple tumor types including reports 
of increased chemosensitivity to GCB in pancreatic cancer85, erlotinib and chemotherapy 
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in NSCLC86, and increased responses to docetaxel in prostate cancer87. However, only 
limited preclinical data exists for the use of OGX-427 in osteosarcoma and no sarcoma 
patients were included in the phase I trials.88 
 
Heat Shock Protein 27 in Osteosarcoma 
Two small series have evaluated the expression and prognostic significance of 
HSP27 in osteosarcoma. HSP27 is overexpressed in 22-24% of patients at baseline and 
33-37% at resection following neo-adjuvant chemotherapy.89, 90 Overexpression of 
HSP27 in pretreatment biopsy samples evaluated in 54 patients was associated with 
inferior overall survival in univariate analysis (HR 3.95, [1.67-9.34]) and when adjusted 
for tumor size and histologic subtype (HR 3.26, [1.28-8.31]).89 In a second series from 
the same group examining the prognostic significance of multiple HSPs (27, 47, 60, 70, 
90α, 90β), only HSP27 overexpression at biopsy (p=0.0021) and HSP27 and HSP70 
expression at surgery (p=0.045, and p=0.018 respectively) were significantly associated 
with poor prognosis.90 Similarly, HSP27 overexpression at biopsy was associated with 
inferior overall survival in a multivariate analysis (adjusted HR 2.63, [1.14-6.06]), 
although presumably this series included some of the same patients as the initial study. 
As predictive biomarkers, HSP72 expression by immunohistochemistry91 and antibodies 
to HSP9092 in patient sera prior to initiation of therapy have both been shown to correlate 
with better responses to neoadjuvant chemotherapy. The utility of HSP27 as a potential 
predictive biomarker of chemotherapy response has not been assessed in osteosarcoma. 
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Hypothesis and Aims 
Based upon preclinical data showing a dual role for chemotherapy-induced 
autophagy in osteosarcoma and the correlation between autophagy inhibition and 
pHSP27 expression in vitro, my central hypothesis is that phosphorylated HSP27 
determines the role of autophagy in osteosarcoma and modulates response to preoperative 
chemotherapy. Therefore, HSP27, pHSP27, and/or autophagy may pose novel 
biomarkers and potential therapeutic targets to improve the efficacy of standard MAP 
chemotherapy in patients with osteosarcoma. 
 
In order to test this hypothesis, the following specific aims were studied: 
Aim 1. To determine if autophagy is induced in osteosarcoma tumor specimens following 
preoperative chemotherapy and correlates with pathologic response, prognosis, and 
HSP27/pHSP27 expression. 
 
Aim 2. To determine whether standard chemotherapy can result in either cytotoxic or 
cytoprotective autophagy in osteosarcoma cell lines and determine whether pHSP27 
expression correlates with the cytoprotective function of chemotherapy-induced 
autophagy following treatment with doxorubicin or cisplatin  
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II. Materials and Methods:  
Patients 
The study population for Aim 1 included 260 pediatric and adult patients with 
osteosarcoma evaluated at the University of Texas MD Anderson Cancer Center between 
1985 and 2012 with tissue specimens included on an institutional tissue microarray 
(TMA) that contains 394 specimens. In all cases, the diagnosis was established according 
to the World Health Organization Classification of Tumors by an expert sarcoma 
pathologist. 93 Patients with extraskeletal osteosarcoma were specifically excluded as this 
is considered a separate entity. Clinical data was collected by retrospective chart review. 
Institutional Review Board approval was obtained for this study and was exempt from 
requiring informed consent.   
 
Construction of tissue microarrays 
Decalcified FFPE tissue blocks from osteosarcoma pretreatment biopsies and 
surgical resection specimens (resected primary tumors and resected metastasis) were 
retrieved from the MD Anderson institutional tumor bank. Hematoxylin/eosin stained 
slides from each block were reviewed by a sarcoma pathologist to identify tumor areas. 
Tissue microarrays (TMAs) were constructed with 0.6mm diameter tissue cores from 
representative tumor areas from the FFPE blocks.  
 
Immunohistochemical Studies 
Four-micron thick unstained slides were prepared from formalin-fixed paraffin-
embedded decalcified human osteosarcoma tissue microarrays. Immunohistochemical 
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studies were performed using an autostainer (Bond III/Rx, Leica Biosystems, Buffalo 
Grove, IL) with an anti-human HSP27 monoclonal antibody (1:1000, Thermo Fischer 
Scientific, clone MA3-15) and LC3B (1:50, NanoTools/Axorra, clone 5F10).  
 Immunohistochemical labeling was independently scored by 2 trained sarcoma 
pathologists, both of whom were blinded from the clinical data at the time of assessment. 
Both  percentage of tumoral labeling (0-100%) and the intensity of immunostaining [0 
(negative), 1 (weak), 2 (moderate), 3 (strong)]was evaluated.  
 LC3B was evaluated using previously validated immunohistochemical methods94 
with granular cytoplasmic or punctate staining assessed. Staining of >10% tumor cells 
was considered positive for HSP27 or LC3B expression. In addition, median cut-points 
(≥ vs < median % staining) and staining intensity (negative vs weak/moderate/strong) 
were examined as prognostic factors.   
 
OS cell lines and cell culture   
LM7 is a human metastatic osteosarcoma cell line that was established in the 
Kleinerman Lab by intravenous recycling the parental cell line (SAOS-2) through the 
lungs of nude mice serially through 7 iterations. CCH-OS-D is a human osteosarcoma 
cell line derived from an 18-year-old male with osteosarcoma lung metastasis. LM7, and 
CCH-OS-D metastatic OS cell lines were cultured in Dulbecco’s modified Eagle medium 
containing 10% fetal bovine serum supplemented with antibiotic and nonessential amino 
acids. Cells were maintained in a humidified incubator with 5% CO2 at 37°C.  
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Reagents and antibodies  
Doxorubicin and cisplatin were obtained from the MD Anderson Cancer Center 
pharmacy and dissolved in PBS to desired concentrations. HCQ was purchased from 
Sigma Aldrich and dissolved with water to a concentration of 10mM. RIPA lysis buffer 
(sc-24948) was purchased from Santa Cruz Biotechnology. The following antibodies 
were used for Western blot analysis: Microtubule-associated protein 1 light chain LC3B 
(NB600-1384) was purchased from Novus Biologicals. Beclin (sc-11427) and HSP27 
(sc-13132) were purchased from Santa Cruz Biotechnology. SQSTM1/p62 (5114) was 
obtained from Cell Signaling Technology. p-HSP27 (MAB23141) was purchased from 
R&D Systems. 
 
Cell viability  
Cell viability, Western blot, and human phosphokinase arrays were completed 
using the same methodology as prior studies from our lab.73 Cells were seeded in 12-well 
plates with approximately 0.5 × 105 cells per well and allowed to attach overnight at 
37°C, 5% CO2. Cells were then treated in the following conditions: doxorubicin, 
cisplatin, HCQ, doxorubicin following HCQ pretreatment for 20 minutes, and cisplatin 
following HCQ pretreatment; cells with no treatment served as controls. Cells were 
trypsinized and viability was assessed by trypan blue exclusion assay using an automated 
cell counter (Vi-cell, Beckman Coulter). The incubation time and drug concentrations are 
specified in the results and respective figures. 
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Human phospho-kinase Antibody Array Kit 
LM7 and CCH-OS-D cells were treated with doxorubicin or cisplatin for 48 
hours. Untreated cells were used as a control. The cells were collected and lysed using 
the lysis buffer provided by the manufacturer, and protein concentration was determined 
using the Bradford Protein Assay from Bio-Rad. After blocking, the membranes were 
incubated with 400µg of protein overnight at 4°C. The membranes were washed and 
incubated with Detection Antibody Cocktails. HRP- conjugated Streptavidin antibodies 
and chemniluminescent detection reagents were used to visualize the protein. 
Densitometry was completed using ImageJ software (https://imagej.nih.gov/ij/). 
 
Western blot analysis  
After treatment, whole cell lysates were prepared by lysing the cells with RIPA 
lysis buffer for 30 minutes and centrifuging at 10,000 g at 4°C. Supernatants were 
collected and protein concentration was determined using the Bio-Rad DC protein assay 
kit (500-0113-0115). Equal amounts of protein were subjected to SDS-polyacrylamide 
gels (SDS-PAGE) and transferred onto a nitrocellulose membrane. Membranes were 
blocked in 5% milk or 5% bovine serum albumin for 1 hour and then incubated with 
primary antibody against LC3 (1:1000) or p62 (1:1000). After overnight incubation with 
primary antibodies, membranes were washed and incubated with anti-mouse (1:2000) 
horseradish peroxidase linked whole antibody (from sheep, NA931V; GE Healthcare) or 
anti-rabbit (1:2000) horseradish peroxidase linked whole antibody (from donkey, 
NA934V; GE Healthcare) as a secondary antibody. Signal was detected using ECL 
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reagents (GE Healthcare Life Science). β-actin or GAPDH were used as loading controls. 
Densitometry was completed using ImageJ software (https://imagej.nih.gov/ij/). 
 
Statistical analysis 
Analyses of overall survival (OS) and relapse-free survival (RFS) were performed. 
OS was defined as from the time of diagnosis to the time of death or to the time of last 
contact. RFS was defined as from the time of surgery to the time of relapse or death, 
whichever occurred first or to the time of last contact. The distributions of OS, and RFS 
were estimated by the Kaplan-Meier method.95 Log-rank test was performed to test the 
difference in survival between patient characteristics/biomarkers groups.96 Regression 
analyses of survival data based on the Cox proportional hazard (PH) regression model 
were conducted on OS and RFS.97 For the resection samples and good response, 
landmark analysis method was used and time of surgery would be the starting points of 
OS and RFS.98 Stepwise method was used to build a multivariate Cox PH regression 
model. Functional form, PH assumption, and multicollinearity were examined.  The 
correlation between two continuous factors was measured by Spearman correlation.99 The 
Chi-square test and Fisher’s exact test were used to determine whether proportions of 
patients with factors of interest were equal between patient characteristics/biomarkers 
groups.100 Wilcoxon signed rank test was used to compare biomarker expression of 
paired resection with synchronous metastatic samples, and paired resection with 
metachronous metastatic samples. A two-sided p-value<0.05 was considered statistically 
significant. SAS version 9.4 was used to carry out the computations. Experimental data 
for cell viability studies were analyzed using Graphpad PRISM 6.0 software. 
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III. Results  
Clinical Characteristics 
There were 215 patients with localized osteosarcoma at the time of diagnosis 
(localized patients) and 45 patients with primary metastatic osteosarcoma (metastatic 
patients). The age at diagnosis of all patients ranged from 4.9 to 90.8 with mean and 
median of 24.2 and 18.3, respectively. Metastatic patients (mean= 24.8 years) were 
slightly older than the localized patients (mean= 24.0 years). Tables 3 and 4 show the 
clinical characteristics in all patients and by stage at presentation (localized disease and 
metastatic disease).  
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Factor n Min Median Mean Max SD 
All patients       
Age at diagnosis (years) 260 4.9 18.3 24.2 90.8 15.8 
Tumor necrosis (%) (patients with pre-op 
chemo) 241 0 87.0 76.0 100 27.0 
 
 
     Localized disease at diagnosis       
Age at diagnosis (years) 215 4.9 18.2 24.0 90.8 15.6 
Tumor Necrosis (%) (patients with pre-op 
chemo) 205 0 86.0 76.1 100 27.2 
       
Metastatic disease at diagnosis  
     Age at diagnosis (years) 45 7.2 20 24.8 78.2 16.9 
Tumor necrosis (%) (patients with pre-op 
chemo) 36 0 88 75.0 100 25.9 
 
Table 3. Clinical and pathologic characteristics by stage at presentation (continuous 
factors). 
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Factor All patients 
Localized 
Disease 
Metastatic 
Disease 
 n (%) n (%) n (%) 
Gender 
   Male 153 (59) 126 (59) 27 (60) 
Female 107 (41) 89 (41) 18 (40) 
Race 
   Asian 9 (3) 7 (3) 2 (4) 
Black 35 (14) 28 (13) 7 (16) 
Hispanic 75 (29) 63 (29) 12 (27) 
White 140 (54) 116 (54) 24 (53) 
Histologic Subtype 
   Osteoblastic 110 (42) 91 (42) 19 (42) 
Chondroblastic 49 (19) 40 (19) 9 (20) 
Fibroblastic 46 (18) 39 (18) 7 (16) 
Telangiectatic 23 (9) 18 (8) 5 (11) 
Dedifferentiated parosteal 12 (5) 10 (5) 2 (4) 
Small cell 6 (2) 4 (2) 2 (4) 
High grade surface 3 (1) 3 (1) 
 Other - high grade 6 (2) 5 (2) 1 (2) 
Other intermediate/low grade 5 (2) 5 (2) 
 Radiation Induced Osteosarcoma    
No 250 (97) 207 (96) 43 (100) 
Yes 8 (3) 8 (4)  
Primary Site    
Femur 140 (54) 112 (52) 28 (62) 
Tibia 43 (17) 39 (18) 4 (9) 
Fibula 10 (4) 9 (4) 1 (2) 
Humerus 32 (12) 24 (11) 8 (18) 
Radius/ulna 3 (1) 3 (1) 
 Mandible 1 (0) 1 (0) 
 Rib/chest wall 7 (3) 4 (2) 3 (7) 
Pelvis/acetabulum 18 (7) 17 (8) 1 (2) 
Other upper extremity 2 (1) 2 (1) 
 Other lower extremity 1 (0) 1 (0) 
 Other axial skeleton 2 (1) 2 (1) 
  
Table 4. Clinical and pathologic characteristics by stage at presentation (categorical 
factors). 
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Factor All patients 
Localized 
Disease 
Metastatic 
Disease 
 n (%) n (%) n (%) 
Grade 
   Low 6 (2) 6 (3) 
 Intermediate 1 (0) 1 (0) 
 High 253 (97) 208 (97) 45 (100) 
Good response (patients receiving pre-op 
chemo)    
No 133 (55) 113 (55) 20 (56) 
Yes 108 (45) 92 (45) 16 (44) 
 
Table 4 (continued). Clinical and pathologic characteristics by stage at presentation 
(categorical factors). 
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Relapse-free and overall survival for osteosarcoma patients with localized disease  
Amongst patients with localized disease at diagnosis, there were 122 relapses and 
deaths during the follow-up period. Ninety-three patients are alive without relapse. Table 
5 shows the log-rank test results for clinical characteristics related to relapse-free 
survival. Patients with radiation induced osteosarcoma had inferior RFS than compared to 
patients without radiation induced osteosarcoma (Figure 4, p=0.0050). 
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Factor p-value 
Gender 0.435 
Race 0.828 
Histologic Subtype 0.737 
Histologic Subtype (Osteoblastic) 0.361 
Radiation Induced osteosarcoma 0.0050 
Primary Site 0.192 
Primary Site (femur) 0.951 
Grade (High/Intermediate vs Low) 0.151 
Pre-op Chemo 0.525 
Good response (patients receiving pre-op chemo)* 0.301 
*Landmark analysis method 
 
Table 5. Log-rank test for relapse-free survival amongst patients with localized disease at 
diagnosis. Radiation-induced osteosarcoma was the only clinical or pathologic 
characteristic that was significantly associated with RFS. 
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Figure 4. Relapse-free survival for patients with localized disease by radiation-induced 
subtype. Patients with radiation-induced osteosarcoma demonstrate inferior RFS. 
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Clinical and pathologic patient characteristics associated with RFS were analyzed 
using a univariate Cox model. Radiation induced osteosarcoma was significantly 
associated with poor RFS (HR: 2.85 [1.33-6.12], p=0.007) compared without radiation 
induced osteosarcoma (Table 6). 
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  Univariate analysis 
Factor 
No. of 
deaths 
Total 
n HR (95% CI) 
P-
value 
Age at diagnosis 121 215 1.01 (1.00, 1.02) 0.133 
     
Sex     
Female 40 89 Ref  
Male 65 126 1.16 (0.80, 1.67) 0.435 
Radiation Induced Osteosarcoma   
 
 
No 98 207 Ref  
Yes 7 8 2.85 (1.33, 6.12) 0.007 
Primary Site (femur vs others)   
 
 
Others 48 103 Ref  
Femur 57 112 1.01 (0.71, 1.45) 0.951 
Grade (High/Intermediate vs low)   
 
 
Low 1 6 Ref  
High/ Intermediate 104 209 2.68 (0.66, 10.8) 0.168 
Pre-op Chemo   
 
 
No 2 7 Ref  
Yes 103 208 1.45 (0.46, 4.56) 0.527 
Good response (patients with pre-op 
chemo)*   
 
 
Yes 43 92 Ref  
No 59 113 1.21 (0.84, 1.75) 0.302 
*Landmark analysis method 
 
Table 6. Relapse-free survival analysis for patients with localized disease (univariate Cox 
regression model).  
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Amongst patients with localized osteosarcoma, there were 105 deaths during the 
follow-up period; 110 patients were alive at the time of analysis. The median follow-up 
time was 11.0 years. The estimated overall survival (OS) was 12.0 years (95% CI 7.03-
20.3). Table 7 shows the log-rank test results for clinical characteristics related to overall 
survival. Patients with radiation induced osteosarcoma had inferior OS as compared to 
patients without radiation induced osteosarcoma (Figure 5, p=0.0003). 
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Factor p-value 
Gender 0.615 
Race 0.597 
Histologic Subtype 0.682 
Histologic Subtype (Osteoblastic vs others) 0.726 
Radiation Induced osteosarcoma 0.0003 
Primary Site 0.162 
Primary Site (femur vs others) 0.555 
Grade (High/Intermediate vs Low) 0.119 
Pre-op Chemo 0.574 
Good response (patients with Pre-op chemo)* 0.0958 
*Landmark analysis method 
 
Table 7. Log-rank test for overall survival amongst patients with localized disease at 
diagnosis. Radiation-induced osteosarcoma was the only clinical or pathologic 
characteristic that was significantly associated with OS. Good response (pathologic tumor 
necrosis >90%) showed a trend toward significance. 
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Figure 5. Overall survival for patients with localized disease by radiation-induced 
subtype. Patients with radiation-induced osteosarcoma demonstrate inferior OS. 
  
  
38 
 
Clinical and pathologic patient characteristics associated with OS amongst 
patients with localized osteosarcoma were analyzed using a univariate and multivariate 
Cox models. Higher age at diagnosis (HR 1.02 [1.00-1.03], p=0.0063) and radiation-
associated osteosarcoma (HR 3.76 [1.74-8.12], p=0.001) were significantly associated 
with inferior overall survival in a univariate model; these factors remained significant in 
multivariate analysis (all p < 0.03, Table 8). Patients with poor response to pre-operative 
chemotherapy showed a trend toward inferior overall survival in a landmark analysis (HR 
1.4 [0.94-2.07], p=0.097). 
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   Univariate analysis  Multivariate analysis 
Factor 
No. of 
deaths 
Tot
al HR (95% CI) 
P-
value 
 
HR (95% CI) 
P-
value 
Age at diagnosis 
(years) 105 215 
1.02 (1.00, 
1.03) 
0.006
3 
 1.01 (1.00, 
1.03) 0.0294 
        
Sex        
Female 40 89 Ref 
 
   
Male 65 126 
1.11 (0.75, 
1.64) 0.615 
 
  
Radiation 
Induced 
osteosarcoma   
  
 
  
No 98 207 Ref 
 
 Ref  
Yes 7 8 
3.76 (1.74, 
8.12) 0.001 
 3.08 (1.38, 
6.86) 0.0061 
Primary Site 
(femur vs others)   
  
 
  
Others 48 103 Ref 
 
   
Femur 57 112 
1.10 (0.76, 
1.65) 0.556 
 
  
Grade 
(High/Intermediat
e vs low)   
  
 
  
Low 1 6 Ref 
 
   
High/ 
Intermediate 104 209 
4.23 (0.59, 
30.4) 0.152 
 
  
Pre-op Chemo   
  
   
No 2 7 Ref 
 
   
Yes 103 208 
1.49 (0.37, 
6.05) 0.577 
 
  
Good response 
(patients with 
pre-op chemo)*   
  
 
  
Yes 43 92 Ref 
 
   
No 59 113 
1.40 (0.94, 
2.07) 0.097 
 
  
*Landmark analysis method 
 
Table 8. Overall survival analysis for patients with localized disease (univariate and 
multivariate Cox regression models).  
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Progression-free and overall survival for patients with metastatic osteosarcoma 
Patients with primary metastatic disease at the time of diagnosis have inferior 
outcomes. Because this is a well-established poor prognostic group, survival outcomes 
and biomarkers for patients with metastasis at diagnosis were analyzed separately from 
patients with localized osteosarcoma.   
Among the 45 patients with primary metastatic disease, 32 (71%) died during the 
follow-up period, with a median follow up of 10.6 years. The median overall survival 
was 2.47 years (95%CI 1.70-3.51). Patients with poor response to pre-operative 
chemotherapy had inferior progression-free survival (HR 2.4 [1.11-5.22]; table 9). 
Patients who did not receive preoperative chemotherapy also had inferior PFS (2 patients, 
HR 6.14 [1.34- 28.1]). Failure to receive preoperative chemotherapy was associated with 
inferior OS (log-rank p=0.0045; Cox HR 6.82 [1.47-31.7]). This likely represents 
patients who were too critically ill at the time of presentation to receive chemotherapy 
and/or surgery. No other clinical characteristics analyzed were significantly associated 
with overall survival amongst patients with primary metastatic disease (Tables 10 and 
11). 
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Factor 
No. of 
deaths/ 
progression 
Total 
n 
Hazard ratio (95% 
CI) 
P-
value 
Age at diagnosis   1.01 (0.99, 1.03) 0.380 
     
sex     
Female 14 18 Ref 
 Male 22 27 1.02 (0.52, 2.00) 0.945 
Histologic Subtype (Osteoblastic)   
  Others 20 26 Ref 
 Osteoblastic 16 19 1.05 (0.54, 2.03) 0.886 
Primary site (Femur)   
  Others 12 17 Ref 
 Femur 24 28 1.42 (0.71, 2.85) 0.323 
Pre-op Chemo     
Yes 29 38 Ref  
No 2 2 6.14 (1.34, 28.1) 0.019 
Good Response (with Pre-op 
Chemo)*   
  Yes 10 16 Ref 
 No 19 22 2.40 (1.11, 5.22) 0.027 
*Landmark analysis method 
 
 
Table 9. Progression-free survival analysis for patients with primary metastatic disease 
(univariate Cox regression model).   
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Factor p-value 
Gender 0.595 
Race 0.551 
Histologic Subtype 0.275 
Histologic Subtype (Osteoblastic vs others) 0.669 
Primary Site 0.0448 
Primary Site (femur vs others) 0.444 
Pre-op Chemo 0.0045 
Good response (patients with pre-op Chemo)* 0.554 
* *Landmark analysis method 
 
 
Table 10. Log-rank test for overall survival amongst patients with metastatic disease at 
diagnosis. Failure to receive preoperative chemotherapy was the only factor associated 
with OS. Of note, only 2 patients did not receive preoperative chemotherapy. 
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Factor No. of deaths Total n HR (95% CI) p-value 
Age at diagnosis 32 45 
1.01 (0.99, 
1.03) 0.496 
     
Sex     
Male 19 27 Ref 
 
Female 13 18 
1.21 (0.60, 
2.46) 0.596 
Histologic Subtype 
(Osteoblastic)   
  Others 17 26 Ref 
 
Osteoblastic 15 19 
1.17 (0.57, 
2.37) 0.669 
Primary site (Femur)   
  Others 11 17 Ref 
 
Femur 21 28 
1.33 (0.64, 
2.77) 0.445 
Pre-op Chemo     
Yes 25 38 Ref  
No 2 2 
6.82 (1.47, 
31.7) 0.014 
Good Response (with Pre-
op Chemo)*   
  Yes 10 16 Ref 
 
No 14 21 
1.28 (0.57, 
2.89) 0.555 
*Landmark analysis method 
 
Table 11. Overall survival analysis for patients with primary metastatic disease 
(univariate Cox regression model).  
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Expression of HSP27 and LC3 in Osteosarcoma Patient Samples 
The osteosarcoma tissue microarray included 394 osteosarcoma tumor specimens 
consisting of 116 pre-treatment biopsies, 184 primary resection specimens, and 94 
metastatic tumor specimens.  Metastatic specimens included a combination of 
synchronous metastasis (26, 28%) and metachronous metastasis (68, 72%). Due to the 
fragility of samples following the decalcification and staining process, not all sample 
were evaluable for all biomarkers analyzed.  
 
LC3B expression in osteosarcoma patient samples 
The percentage of osteosarcoma cells with clearly visible cytoplasmic LC3B+ 
puncta labeling were quantified, with ≥10% considered positive based upon established 
cutoffs in other tumor types.56 LC3B+ expression was significantly higher in resection 
specimens and metastasis as compared to pre-treatment biopsies (50% and 67% 
respectively vs 34%, p=0.004). Examples of LC3B labeling are shown in Figure 6. The 
intensity of cytoplasmic LC3B staining was heterogeneous. A higher proportion of pre-
treatment biopsy specimens were graded as 0 or negative (66%) as compared to resection 
(47%) or metastasis (30%, Table 12). 
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Figure 6. Examples of LC3B labeling in osteosarcoma tumor specimens and normal 
lung. Punctate labeling (A) as well as granular cytoplasmic labeling (B) in osteosarcoma 
tumor cells were considered positive. In normal human lung tissue, pneumocytes are 
negative for LC3B whereas macrophages stain positive (C). 
 
LC3B Expression in Patient Samples 
Factor All Biopsy Resection Metastatic 
  n (%) n (%) n (%) n (%) 
LC3B intensity 
    None 122 (47) 38 (66) 64 (47) 20 (30) 
Weak 82 (31) 7 (12) 43 (31) 32 (48) 
Moderate 54 (21) 11 (19) 29 (21) 14 (21) 
Strong 3 (1) 2 (3) 1 (1) 
 LC3B percent (10% as 
cutoff) 
    <10% 128 (49) 38 (66) 68 (50) 22 (33) 
≥10% 133 (51) 20 (34) 69 (50) 44 (67) 
 
Table 12. Punctate LC3B expression in osteosarcoma patient samples by IHC. Samples 
scored by intensity and percent of tumor cells expressing LC3B+ puncta.  
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Paired pre-treatment biopsy and post-treatment resection specimens were 
available for LC3B puncta evaluation in 18 patients, including 9 LCB+ at biopsy and 9 
LC3B negative prior to treatment. Five of 9 patients (56%) who were initially negative 
for LC3B puncta were positive for the autophagy marker at the time of resection 
following chemotherapy. Conversely, 8/9 patients (89%) who were positive prior to 
chemotherapy remained positive at resection (Table 13). These findings suggest that the 
presence of LC3B puncta at resection may represent chemotherapy-induced autophagy in 
a subset of patients. Similarly, amongst 6 patients with negative LC3B expression in pre-
treatment samples, 3 subsequently had LC3B+ puncta in metachronous metastatic 
specimens and 3 remained negative. Resection-metastasis pairs were available in 26 
patients. Amongst 13 who were negative for LC3B expression at resection, 9 (69%) 
demonstrated LC3B+ puncta in metachronous metastatic specimens (Table 13). 
Differences in LC3B expression amongst the pairs were not statistically significant, 
however this may be due to the small sample size. 
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LC3B+ (10% cutoff) in paired biopsy-resection specimens 
  Resection   McNemar's test p-value 
Biopsy <10% ≥10% 0.103 
<10% 4 5   
≥10% 1 8   
LC3B+ (10% cutoff) in paired biopsy-metastasis specimens 
  Metastasis   McNemar's test p-value 
Biopsy <10% ≥10% 0.0833 
<10% 3 3   
≥10% 0 2   
LC3B+ (10% cutoff) in paired resection-metastasis specimens 
  Metastasis   McNemar's test p-value 
Resection <10% ≥10% 0.166 
<10% 4 9   
≥10% 4 9   
 
Table 13. LC3B puncta in paired osteosarcoma tumor specimens.  
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HSP27 and pHSP27 expression in osteosarcoma patient samples 
The percent and intensity of HSP27 expression was variable, with some tumor 
having strong diffuse expression in tumor cells and others having no appreciable HSP27 
expression (Figure 7).  
 
 
Figure 7. Representative expression of HSP27 in osteosarcoma tumor specimens. 
Expression was variable, with some tumor having strong, diffuse staining (A) and others 
showing no expression (B). 
The percentage of osteosarcoma cells with HSP27 staining was quantified, with ≥10% 
considered positive. Two-thirds of all tumor specimens analyzed were scored as positive 
for HSP27 expression. The proportion of HSP27+ tumors was higher in pre-treatment 
biopsy (85%) and metastasis specimens (79%) as compared to resection (52%), although 
this was not statistically significant. The intensity of HSP27 staining was variable across 
all groups. There was no significant correlation between HSP27 expression and LC3B 
expression (Spearman correlation 0.006, p=0.945). HSP27 expression is summarized in 
table 14. 
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HSP27 Expression in Patient Samples 
Factor All Biopsy Resection Metastatic 
  n (%) n (%) n (%) n (%) 
HSP27 intensity 
    None 41 (16) 9 (16) 28 (21) 4 (6) 
Weak 144 (57) 28 (48) 74 (56) 42 (67) 
Moderate 38 (15) 16 (28) 13 (10) 9 (14) 
Strong 29 (12) 5 (9) 16 (12) 8 (13) 
 
    HSP27 percent (10% as 
cutoff) 
    <10% 85 (34) 9 (15) 63 (48) 13 (21) 
≥10% 168 (66) 50 (85) 68 (52) 50 (79) 
 
Table 14. Heat shock protein 27 (HSP27) expression in osteosarcoma patient samples by 
IHC. Samples scored by intensity and percent of tumor cells expressing HSP27.  
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The percentage and intensity of osteosarcoma cells with phosphorylated HSP27 
(pHSP27 S78/S82) staining was quantified. The expression of pHSP27 was very limited 
(representative staining shown in figure 8) at all time points, with only 16% of all 
specimens tested showing any staining and 8% considered positive (pHSP27 >10%; table 
15). This likely reflects a degradation of phosphoproteins in the acquisition and 
processing (decalcification) of bone tumor specimens, rather than a true lack of pHSP27.  
Due to the limited labeling, no significant inferences could be made regarding the 
prognostic significance of pHSP27 or its correlation with other biomarkers of interest.  
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Figure 8. Representative expression of pHSP27 in osteosarcoma tumor specimens.  
 
pHSP27 Expression in Patient Samples 
Factor All Biopsy Resection Metastatic 
  n (%) n (%) n (%) n (%) 
pHSP27 intensity 
    None 241 (84) 44 (77) 133 (88) 64 (82) 
Weak 39 (14) 11 (19) 16 (11) 12 (15) 
Moderate 4 (1) 2 (4) 2 (1) 
 Strong 3 (1) 
 
1 (1) 2 (3) 
pHSP27 percent (10% as 
cutoff) 
    <10% 264 (92) 44 (77) 143 (94) 77 (99) 
≥10% 23 (8) 13 (23) 9 (6) 1 (1) 
 
Table 15. Phosphorylated heat shock protein 27 (pHSP27 S78/S82) expression in 
osteosarcoma patient samples by IHC. Samples scored by intensity and percent of tumor 
cells expressing HSP27.  
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Prognostic Significance of HSP27 Expression and LC3B Puncta in Osteosarcoma 
Patients  
 
LC3B as a prognostic biomarker in localized osteosarcoma 
The presence of LC3B puncta labeling in pre-treatment specimens was not 
associated with relapse-free or overall survival. Localized osteosarcoma patients with 
LC3B puncta staining present at resection (which was found in 50% of cases) had 
superior overall survival (Figure 9, p=0.031).  
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Figure 9. Overall survival for localized osteosarcoma patients stratified according to 
cytoplasmic LC3B puncta expression at resection (>10% positive, <10% negative) 
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The lack of LCB puncta labeling at resection was associated with inferior relapse-
free survival in univariate analysis (HR 1.81 [1.10-2.98], p=0.019) but only maintained 
borderline significance when adjusted for radiation-induced osteosarcoma in the 
multivariate model (HR 1.65 [0.99-2.75], p=0.053; table 16). This lack of LC3B at 
resection following chemotherapy was significantly associated with inferior overall 
survival in both the univariate (HR 1.78 [1.05-3.03], p=0.034) and multivariate analysis 
(HR 1.75 [1.01-3.04], p=0.045) when adjusted for age and radiation-induced 
osteosarcoma (Table 17). A median cutpoint was also explored and found to yield 
prognostic significance: patients with LC3B ≤ median at resection had inferior relapse 
free (lor rank p=0.004) and overall survival (log rank p=0.0068). Taken together, our 
findings suggest that presence of LC3B puncta can be considered an independent 
prognostic biomarker of improved survival following preoperative chemotherapy.   
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   Univariate  Multivariate* 
Factor 
No. of 
deaths 
Tota
l n HR (95% CI) P-value 
 
HR (95% CI) P-value 
HSP27 intensity   
  
   
None 10 22 Ref 
 
 Ref  
Weak, moderate, strong 52 81 1.76 (0.89, 3.49) 0.107  1.68 (0.84, 3.33) 0.141 
HSP27 intensity        
None, weak 43 78 Ref   Ref  
Moderate, strong 19 25 1.70 (0.98, 2.96) 0.0598  1.86 (1.06, 3.26) 0.0307 
HSP27 percent (median)   
  
   
≤ median 28 55 Ref 
 
 Ref  
> median 34 48 1.74 (1.04, 2.91) 0.0336  1.57 (0.93, 2.66) 0.0912 
HSP27 percent (10%)   
  
   
<10% 22 47 Ref 
 
 Ref  
≥10% 40 56 1.92 (1.13, 3.28) 0.016  1.76 (1.03, 3.03) 0.0398 
pHSP27 intensity   
  
   
None 63 103 Ref 
 
 Ref  
Weak, moderate, strong 11 17 1.21 (0.63, 2.29) 0.568  1.28 (0.67, 2.44) 0.456 
pHSP27 percent (median)   
  
   
≤ median 63 103 Ref 
 
 Ref  
> median 11 17 1.21 (0.63, 2.29) 0.568  1.28 (0.67, 2.44) 0.456 
pHSP27 percent (10%)   
  
   
<10% 68 111 Ref 
 
 Ref  
≥10% 6 9 1.25 (0.54, 2.89) 0.6  1.30 (0.56, 3.01) 0.538 
LC3 intensity   
  
   
Weak, moderate, strong 28 56 Ref 
 
 Ref  
None 38 51 1.82 (1.11, 2.97) 0.0174  1.65 (1.00, 2.73) 0.0525 
LC3 intensity        
Moderate, strong 13 27 Ref   Ref  
None, weak 53 80 1.32 (0.72, 2.43) 0.374  1.24 (0.67, 2.29) 0.488 
LC3 percent (median)   
  
   
> median 22 48 Ref 
 
 Ref  
≤ median 44 59 2.09 (1.25, 3.50) 0.0051  1.93 (1.14, 3.25) 0.0142 
LC3 percent (10%)   
  
   
≥10% 26 53 Ref 
 
 Ref  
<10% 40 54 1.81 (1.10, 2.98) 0.0192  1.65 (0.99, 2.75) 0.0527 
*Adjusting for radiation induced osteosarcoma 
 
Table 16. Univariate and multivariate analyses (Cox regression) for biomarkers at 
resection associated with RFS.  
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   Univariate  Multivariate* 
Factor 
No. of 
deaths Total n HR (95% CI) 
P-
value  HR (95% CI) 
P-
value 
HSP27 intensity   
  
   
None 7 22 Ref 
 
 Ref  
Weak, moderate, 
strong 46 81 2.11 (0.95, 4.73) 0.0683  2.13 (0.95, 4.78) 0.0661 
HSP27 intensity        
None, weak 35 78 Ref   Ref  
Moderate, strong 18 25 2.02 (1.14, 3.59) 0.0166  2.27 (1.26, 4.11) 0.0065 
HSP27 percent 
(median)   
  
   
≤ median 23 55 Ref 
 
 Ref  
> median 30 48 1.72 (0.99, 2.98) 0.0541  1.53 (0.87, 2.68) 0.137 
HSP27 percent (10%)   
  
   
<10% 18 47 Ref 
 
 Ref  
≥10% 35 56 2.00 (1.12, 3.56) 0.0197  1.85 (1.03, 3.33) 0.0395 
pHSP27 intensity   
  
   
None 54 103 Ref 
 
 Ref  
Weak, moderate, 
strong 10 17 1.33 (0.67, 2.61) 0.413  1.32 (0.67, 2.63) 0.423 
pHSP27 percent 
(median)   
  
   
≤ median 54 103 Ref 
 
 Ref  
> median 10 17 1.33 (0.67, 2.61) 0.413  1.32 (0.67, 2.63) 0.423 
pHSP27 percent (10%)   
  
   
<10% 59 111 Ref 
 
 Ref  
≥10% 5 9 1.09 (0.44, 2.71) 0.860  1.14 (0.46, 2.85) 0.778 
LC3 intensity   
  
   
Weak, moderate, 
strong 24 56 Ref 
 
 Ref  
None 34 51 1.78 (1.05, 3.00) 0.0315  1.69 (0.99, 2.90) 0.0556 
LC3 intensity        
Moderate, strong 11 27 Ref   Ref  
None, weak 47 80 1.34 (0.69, 2.60) 0.382  1.34 (0.69, 2.61) 0.395 
LC3 percent (median)   
  
   
> median 18 48 Ref 
 
 Ref  
≤ median 40 59 2.12 (1.21, 3.70) 0.0082  2.15 (1.21, 3.81) 0.0089 
LC3 percent (10%)   
  
   
≥10% 22 53 Ref 
 
 Ref  
<10% 36 54 1.78 (1.05, 3.03) 0.0337  1.75 (1.01, 3.04) 0.0448 
*Adjusting for age and radiation induced osteosarcoma 
 
Table 17. Univariate and multivariate analyses (Cox regression) for biomarkers at 
resection associated with OS.  
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HSP27 as a prognostic biomarker in localized osteosarcoma 
The majority of osteosarcoma specimens were scored as HSP27+ in pre-treatment 
samples. While HSP27+ in pre-treatment samples was not significant in univariate 
analysis for relapse free survival or overall survival, it was associated with inferior 
relapse-free survival (HR: 12.5 [1.34-116], p=0.027) and overall survival (HR: 26.7 
[1.47-484], p=0.0263) in multivariate analysis (tables 18 and 19, respectively). At 
resection, patients with HSP27+ osteosarcoma had inferior overall survival (Figure 10, 
p=0.017). HSP27+ in resection specimens was associated with inferior relapse-free 
survival in both the univariate (HR 1.92 [1.13-3.28], p=0.016) and multivariate models 
(HR 1.76 [1.03-3.03], p=0.039; table 16) as well as worse overall survival (univariate HR 
2.00 [1.12-3.56], p=0.0197, multivariate HR: 1.85 [1.03-3.33], p=0.039; table 17). A 
median cutpoint and stratification by intensity (none/weak vs. moderate/strong) was also 
explored and showed a similar trend with high expression of HSP27 associated with 
inferior outcomes. However neither measure was statistically significant in both the 
univariate and multivariate models for both RFS and OS (at resection summarized in 
tables 16 and 17; pre-treatment specimens in tables 18 and 19).  
Phosphorylated HSP27 was evaluated as a potential biomarker based upon the 
initial hypothesis. There were no significant associations between pHSP27 expression 
based upon percent staining, median cutoff, or intensity prior to treatment or at resection 
in relation to either RFS or OS. Further, there was no correlation between pHSP27 
positivity (any criteria) and total HSP27 nor LC3B.   
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   Univariate  Multivariate* 
Factor 
No. of 
deaths 
Total 
n HR (95% CI) P-value  HR (95% CI) P-value 
HSP27 intensity        
None 2 8 Ref   Ref  
Weak, moderate, 
strong 18 41 2.41 (0.55, 10.6) 0.243  11.5 (1.27, 105) 0.0299 
HSP27 intensity        
None, weak 10 30 Ref   Ref  
Moderate, strong 10 19 2.01 (0.84, 4.85) 0.119  2.60 (1.01, 6.73) 0.0487 
HSP27 percent 
(median)        
≤ median 11 27 Ref   Ref  
> median 10 23 1.12 (0.47, 2.64) 0.798  1.35 (0.55, 3.32) 0.512 
HSP27 percent (10%)        
<10% 2 8 Ref   Ref  
≥10% 19 42 2.48 (0.57, 10.8) 0.226  12.5 (1.34, 116) 0.0265 
pHSP27 intensity        
Weak, moderate, 
strong 4 12 Ref   Ref  
None 15 36 1.29 (0.43, 3.88) 0.655  1.16 (0.38, 3.53) 0.801 
pHSP27 percent 
(median)        
> median 4 12 Ref   Ref  
≤ median 15 36 1.29 (0.43, 3.88) 0.655  1.16 (0.38, 3.53) 0.801 
pHSP27 percent (10%)        
≥10% 4 12 Ref   Ref  
<10% 15 36 1.29 (0.43, 3.88) 0.655  1.16 (0.38, 3.53) 0.801 
LC3 intensity        
Weak, moderate, 
strong 4 16 Ref   Ref  
None 13 34 1.62 (0.53, 4.99) 0.399  1.50 (0.48, 4.67) 0.483 
LC3 intensity        
Moderate, strong 2 10 Ref   Ref  
None, weak 15 40 2.03 (0.46, 8.89) 0.35  1.90 (0.43, 8.39) 0.398 
LC3 percent (median)        
> median 4 16 Ref   Ref  
≤ median 13 34 1.62 (0.53, 4.99) 0.399  1.50 (0.48, 4.67) 0.483 
LC3 percent (10%)        
≥10% 4 16 Ref   Ref  
<10% 13 34 1.62 (0.53, 4.99) 0.399  1.50 (0.48, 4.67) 0.483 
*Adjusting for radiation induced osteosarcoma 
Table 18. Univariate and multivariate analyses (Cox regression) for biomarkers assessed 
in pre-treatment biopsy specimens associated with RFS.   
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   Univariate  Multivariate* 
Factor 
No. of 
deaths 
Total 
n HR (95% CI) P-value  HR (95% CI) 
P-
value 
HSP27 intensity   
  
   
None 1 8 Ref 
 
 Ref  
Weak, moderate, strong 15 41 3.68 (0.49, 28.0) 0.207  23.1 (1.34, 397) 0.0306 
HSP27 intensity        
None, weak 8 30 Ref   Ref  
Moderate, strong 8 19 1.90 (0.71, 5.09) 0.201  2.39 (0.84, 7.10) 0.117 
HSP27 percent (median 
as cutoff)   
  
   
≤ median 8 27 Ref 
 
 Ref  
> median 9 23 1.52 (0.59, 3.97) 0.388  1.85 (0.68, 5.01) 0.227 
HSP27 percent (10%)   
  
   
<10% 1 8 Ref 
 
 Ref  
≥10% 16 42 3.78 (0.50, 28.6) 0.198  26.7 (1.47, 484) 0.0263 
pHSP27 intensity        
Weak, moderate, strong 3 12 Ref   Ref  
None 11 36 1.18 (0.33, 4.27) 0.796  1.20 (0.32, 4.49) 0.787 
pHSP27 percent 
(median as cutoff)        
> median 3 12 Ref   Ref  
≤ median 11 36 1.18 (0.33, 4.27) 0.796  1.20 (0.32, 4.49) 0.787 
pHSP27 percent (10%)        
≥10% 3 12 Ref   Ref  
<10% 11 36 1.18 (0.33, 4.27) 0.796  1.20 (0.32, 4.49) 0.787 
LC3 intensity   
  
   
Weak, moderate, strong 3 16 Ref   Ref  
None 9 34 1.38 (0.37, 5.12) 0.631  1.40 (0.34, 5.82) 0.646 
LC3 intensity        
Moderate, strong 2 10 Ref   Ref  
None, weak 10 40 1.10 (0.24, 5.06) 0.905  1.02 (0.21, 4.84) 0.983 
LC3 percent (median)   
  
   
> median 3 16 Ref   Ref  
≤ median 9 34 1.38 (0.37, 5.12) 0.631  1.40 (0.34, 5.82) 0.646 
LC3 percent (10%)   
  
   
≥10% 3 16 Ref 
 
 Ref  
<10% 9 34 1.38 (0.37, 5.12) 0.631  1.40 (0.34, 5.82) 0.646 
*Adjusting for age and radiation induced osteosarcoma 
 
Table 19. Univariate and multivariate analyses (Cox regression) for biomarkers assessed 
in pre-treatment biopsy specimens associated with OS.  
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Figure 10. Overall survival for localized osteosarcoma patients stratified according to 
HSP27 expression at resection (>10% positive, <10% negative) 
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Combined analysis of LC3B puncta and HSP27 was evaluated for further risk 
stratification amongst patients with localized disease. In pre-treatment biopsy samples 
from 32 evaluable patients, the combination of HSP27+/LC3B- was associated with a 
trend towards inferior survival (log rank p=0.087).  Ninety-two patients with localized 
disease had resection specimens with HSP27 and LC3B biomarker data available for 
analysis. Patients with HSP27-/LC3B+ tumors had significantly improved overall 
survival as compared to all others (p=0.012, Figure 11). This was stratified into 4 groups 
with HSP27-/LC3B+ having favorable outcomes, HSP27+/LC3B+ or HSP27-/LC3B- 
with intermediate risk, and HSP27+/LC3B- having the worst overall survival (p=0.018, 
Figure 12). 
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Figure 11. Overall survival for localized osteosarcoma patients combined biomarker 
analysis at resection, HSP27-/LC3B+ vs all others. HSP27-/LC3B+ patients have 
significantly improved OS as compared to all others. 
  
63 
 
Figure 12. Overall survival for localized osteosarcoma patients stratified by combined 
biomarker analysis at resection yields 3 risk groups: good risk (HSP27-/LC3B+), 
intermediate risk (HSP27+/LC3B+ or HSP27-/LC3B-), or poor risk (HSP27+/LC3B-). 
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Pathologic treatment response assessed by percent tumor necrosis following 
neoadjuvant chemotherapy is the most well established prognostic marker in patients 
with localized osteosarcoma. Neither LC3B percentage nor HSP27 percentage expression 
in pre-treatment specimens correlated with percent tumor necrosis following neoadjuvant 
chemotherapy (Spearman correlation -0.12, p=0.384 and -0.067, p=0.655 respectively). 
Further, there was no association between LC3B+ puncta in pre-treatment samples and a 
good pathologic response to chemotherapy (p=0.391) nor between HSP27+ and good 
pathologic response (p=1.00, Table 20). Additionally, no significant association was seen 
between either marker at resection and a good response to therapy (data not shown). In a 
subset of localized OS patients with poor response to therapy (tumor necrosis <90%), the 
lack of LC3B puncta was associated with a trend toward inferior overall survival (HR: 
1.87 [0.96-3.64], p=0.0665; Figure 13).  
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 Factor 
Poor  
response 
Good 
response  
Poor 
response 
Good 
response P-value 
 
n (Column 
%) 
n (Column 
%)  
n (row 
%) 
n (row 
%)  
HSP27 intensity 
  
   1a 
None 3 (14) 4 (13)  3 (43) 4 (57) 
 Weak, moderate, strong 19 (86) 26 (87)  19 (42) 26 (58) 
 HSP27 intensity      0.756b 
None 13 (59) 19 (63)  13 (41) 19 (59)  
Weak, moderate, strong 9 (41) 11 (37)  9 (45) 11 (55)  
HSP27 percent (median) 
  
   0.758b 
≤ median 13 (59) 17 (55)  13 (43) 17 (57) 
 > median 9 (41) 14 (45)  9 (39) 14 (61) 
 HSP27 percent (10%) 
  
   1a 
<10% 3 (14) 4 (13)  3 (43) 4 (57) 
 ≥10% 19 (86) 27 (87)  19 (41) 27 (59) 
 LC3 intensity 
  
   0.391b 
None 16 (62) 21 (72)  16 (43) 21 (57) 
 Weak, moderate, strong 10 (38) 8 (28)  10 (56) 8 (44) 
 LC3 intensity      0.831b 
None, weak 20 (77) 23 (79)  20 (47) 23 (53)  
Moderate, strong 6 (23) 6 (21)  6 (50) 6 (50)  
LC3 percent (median) 
  
   0.391b 
≤ median 16 (62) 21 (72)  16 (43) 21 (57) 
 > median 10 (38) 8 (28)  10 (56) 8 (44) 
 LC3 percent (10%) 
  
   0.391b 
<10% 16 (62) 21 (72)  16 (43) 21 (57)  
≥10% 10 (38) 8 (28)  10 (56) 8 (44) 
 a: Fisher’s exact test, b: Chi-square test 
 
Table 20. Association between pre-treatment biomarker expression and pathologic 
treatment response to preoperative chemotherapy. Good pathologic response is defined as 
≥ 90% tumor necrosis at the time of resection. 
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Figure 13. Overall survival for localized osteosarcoma patients with poor response 
pathologic response to preoperative chemotherapy stratified according LC3B+ at 
resection. Amongst poor responders, presence of LC3B+ puncta is associated with a 
trend towards improved OS. 
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HSP27 and LC3B as prognostic biomarkers in primary metastatic osteosarcoma 
The prognostic significance of HSP27 and LC3B in patients with primary 
metastatic disease was evaluated at the time of diagnosis (pre-treatment) and at resection 
for patients who underwent resection of the primary tumor. Due to the limited number of 
samples, no meaningful inferences could be made based upon pretreatment expression of 
either marker. For example, amongst 9 patients with metastatic osteosarcoma who had 
evaluable pretreatment samples, 8/9 (89%) were positive for HSP27 (>10% expression). 
Similarly, at resection, neither LC3B+ (any criteria) nor HSP27+ (any criteria) was 
associated with either PFS or OS. 
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The Dual Role of Chemotherapy-induced Autophagy in Osteosarcoma Cells 
Several studies have evaluated the presence and significance of chemotherapy-
induced autophagy in osteosarcoma cell lines and to a lesser extent, mouse xenograft 
models.64 The majority of these works have focused on autophagy as a mechanism of 
chemoresistance and therefore explore autophagy inhibition as a means to enhance 
chemotherapeutic efficacy. In prior studies from our lab, we have shown that 
chemotherapy-induced autophagy in osteosarcoma can have a dual role, either 
cytoprotective or cytotoxic, following treatment with 9-nitrocamptothecin (9-NC)72 or 
gemcitabine (GCB).73 Further, in a recent paper from our group, we showed that the post-
treatment expression of pHSP27 correlated with the role of autophagy (and treatment 
effect of autophagy inhibition with hydroxychloroquine [HCQ]) in vitro for both 9-NC 
and GCB.   
Both cisplatin and doxorubicin have previously been shown to induce autophagy 
in multiple osteosarcoma cell lines including MG-63, SaOS-2, and U-2 OS amongst 
others. In these studies, standard MAP chemotherapy resulted in chemoresistance, and 
the inhibition of autophagy (either pharmacologic or by shRNA knockdown of key 
autophagy genes) resulted in enhanced chemosensitivity.65-67, 70, 101 To our knowledge, 
however, no preclinical models or in vitro experiments have shown a cytotoxic role for 
autophagy following doxorubin or cisplatin. Based upon our preliminary data with 9-NC 
and GCB in osteosarcoma cell lines in conjunction with the clinical biomarker data 
suggesting a favorable role for autophagy following standard chemotherapy, we sought to 
determine whether standard chemotherapy can result in either cytototxic or cytoprotective 
autophagy in osteosarcoma cell lines and determine whether pHSP27 expression 
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correlates with the cytoprotective function of chemotherapy-induced autophagy following 
treatment with doxorubicin or cisplatin. 
 
Doxorubicin and cisplatin induce autophagy in LM7 and CCH-OS-D  
Changes in key autophagy proteins were evaluated by Western blot to confirm the 
induction of autophagy following treatment with either doxorubicin or cisplatin 
treatment. LC3 and p62 are common markers of autophagy and autophagic flux. Upon 
induction of autophagy, LC3I is conjugated to phosphatidylenthanolamine to form LC3II 
which is then recruited to the autophagosomal membrane and subsequently degraded in 
the autolysosome. This process results in an increase in the LC3II/LC3I ratio that is 
indicative of activation or induction of autophagy. p62, also known as SQSTM1, is often 
used as a protein marker of autophagic flux. When autophagy is induced, p62 is 
incorporated into the autophagosome and is degraded. Thus the combination of an 
increased LC3II/LC3I ratio and decrement in p62 are suggestive of an increase in 
autophagy, and more specifically autophagic flux.57 Finally, the lysosomal inhibitor 
hydroxychloroquine blocks the late-stages of autophagy resulting in an increase in 
LC3II/LC3I. 
Initially, LM7 cells were treated with either doxorubicin (DOX, 0.2 ug/mL), 
cisplatin (CDDP, 20uM), hydroxychloroquine alone (HCQ, 20 uM), or the combination 
of DOX+HCQ, or CDDP+HCQ and collected at 48 hours post-treatment. For the 
combination, cells were pretreated with HCQ for 20 minutes prior to the addition of 
DOX. Evaluation of LC3 showed a modest increase in the LC3II/LC3I ratio for DOX and 
CDDP alone, and as expected, a significant increase LC3II accumulation in all groups 
containing HCQ (Figure 14).  
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Figure 14. DOXO and CDDP increase LC3II expression in LM7 cells. Osteosarcoma 
cells were grown until 70-80% confluent and treated with HCQ (20 uM), DOXO (0.2 
ug/mL), HCQ+DOXO (pretreatment with HCQ for 20 minutes, followed by DOXO), 
CDDP (20 uM), or HCQ+CDDP (pretreatment with HCQ for 20 minutes, followed by 
CDDP). Cells were collected and lysed using RIPA buffer. Equal amounts of total protein 
were resolved in SDS-PAGE, transferred to a nitrocellulose membrane and blotted using 
specific antibodies for LC3. Beta-actin is used as a loading control. Western blot analysis 
and densitometry show increase in LC3II/LC3I ratio following treatment with DOXO or 
CDDP compared to untreated control consistent with induction of autophagy. LC3II 
accumulation is seen in all HCQ containing conditions, consistent with late-autophagy 
inhibition. p62 is needed to confirm the presence of autophagic flux, but was not able to 
be performed. 
  
  
71 
Next, this experiment was repeated for LM7 cells with DOX alone (0.2ug/mL) for 
48 and 72 hours. Under these conditions, induction of autophagy was not readily apparent 
(qualitative expression of p62 and LC3 shown in figure 15). While the HCQ either alone 
or in combination with DOX resulted in an increase accumulation of LC3II, DOX alone 
did not significantly alter either p62 or LC3 expression in comparison to untreated 
controls.  
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Figure 15. Autophagy induction is not apparent with standard doses of DOXO at 48 and 
72 hours in LM7 cells. Osteosarcoma cells were grown until 70-80% confluent and 
treated with HCQ (20 uM), DOXO (0.2 ug/mL), HCQ+DOXO (pretreatment with HCQ 
for 20 minutes, followed by DOXO). Cells were collected and lysed using RIPA buffer. 
Equal amounts of total protein were resolved in SDS-PAGE, transferred to a 
nitrocellulose membrane and blotted using specific antibodies for LC3 and p62. Beta-
actin is used as a loading control. Qualitative changes in p62 and LC3II/LC3I were not 
consistent with autophagy induction, where a decrement in p62 and increase in LC3II 
would be expected. HCQ containing conditions result in increased LC3II accumulation. 
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Subsequently, LM7 cells were treated with escalating doses of DOX (0.2-0.8 
ug/mL) and collected at 24, 48, and 72 hours post-treatment. LC3I to LC3II conversion 
was assessed; DOX+HCQ was used as a positive control. This demonstrated a relative 
increase in the LC3II/LC3I ratio with increasing doses and longer drug exposure (Figure 
16). 
  
  
74 
 
 
 
 
Figure 16. Autophagy induction with DOXO increase with dose and time in LM7 cells. 
Osteosarcoma cells were grown until 70-80% confluent and treated with increasing doses 
of DOXO (0.2 – 0.8 ug/mL) for 24, 48, and 72 hours. DOXO+HCQ was used as a 
positive control. Cells were collected and lysed using RIPA buffer. Equal amounts of 
total protein were resolved in SDS-PAGE, transferred to a nitrocellulose membrane and 
blotted using specific antibodies for LC3. Beta-actin is used as a loading control. Western 
blot analysis and densitometry show increase in LC3II/LC3I ratio at later time points and 
higher doses consistent with induction of autophagy. LC3II accumulation is seen in 
DOX+HCQ consistent with late-autophagy inhibition.  
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Our prior experience with LM7 has shown this cell line to be relatively 
chemoresistant to multiple chemotherapies, having higher IC50 concentrations as 
compared to other human and murine osteosarcoma cell lines. We therefore repeated the 
Western blots for LM7 cells treated at higher doses (DOX 1ug/mL and CDDP 40uM) for 
48 and 72 hours. DOX resulted in an increase in the LC3II/I ratio at both 48 and 72 hours 
but without a concomitant decrease in p62 (Figure 17). CDDP treatment resulted in an 
increase in LC3II/I and a decrement in p62 at 48 but not 72 hours (Figure 18). Overall, 
these finding suggest that both DOX and CDDP can induce autophagy in LM7 cells, 
however the optimal dose and time point for maximal autophaguc flux was not clearly 
identified.  
  
  
76 
 
 
 
Figure 17. DOXO induces autophagy in LM7 cells. Osteosarcoma cells were grown until 
70-80% confluent and treated DOXO (1 ug/mL), HCQ (20 uM), HCQ+DOXO 
(pretreatment with HCQ for 20 minutes, followed by DOXO) and collected at 48 and 72 
hours.  Cells were collected and lysed using RIPA buffer. Equal amounts of total protein 
were resolved in SDS-PAGE, transferred to a nitrocellulose membrane and blotted using 
specific antibodies for LC3 and p62. Actin is used as a loading control. Western blot 
analysis and densitometry show increase in LC3II/LC3I ratio with DOX treatment at 48 
and 72 hours compared to untreated controls; DOX did not result in a decrease in p62. 
Note, densitometry values were normalized to untreated cells at each respective time 
point. 
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Figure 18. CDDP induces autophagy in LM7 cells. Osteosarcoma cells were grown until 
70-80% confluent and treated CDDP (40 uM), HCQ (20 uM), HCQ+CDDP (pretreatment 
with HCQ for 20 minutes, followed by CDDP) and collected at 48 and 72 hours.  Cells 
were collected and lysed using RIPA buffer. Equal amounts of total protein were resolved 
in SDS-PAGE, transferred to a nitrocellulose membrane and blotted using specific 
antibodies for LC3 and p62. Actin is used as a loading control. Western blot analysis and 
densitometry show increase in LC3II/LC3I ratio and decrease in p62 with CDDP 
treatment at 48 as compared to untreated controls consistent with induction of autophagy. 
Note, densitometry values were normalized to untreated cells at each respective time 
point. 
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The results for CCH-OS-D cells were more apparent. CCH-OS-D cells were 
treated with either doxorubicin (DOX, 0.2 ug/mL) or cisplatin (CDDP, 20 uM) for 48 
hours. GCB treatment was used as a positive control. All treatment groups resulted in an 
increase in the LC3II/LC3I ratio and decrement in p62 relative to untreated cells 
consistent with induction of autophagy (Figure 19).   
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Figure 19. DOXO and CDDP induce autophagy in CCH-OS-D cells. Osteosarcoma cells 
were grown until confluent and treated with GCB (1 uM), DOXO (0.2 ug/mL), or CDDP 
(20 uM) for 48 hours. Cells were collected and lysed using RIPA buffer. Equal amounts 
of total protein were resolved in SDS-PAGE, transferred to a nitrocellulose membrane 
and blotted using specific antibodies for LC3 and p62. GAPDH is used as a loading 
control. Western blot analysis and densitometry show increase in LC3II/LC3I ratio and 
decrease in p62 following treatment with GCB, DOXO, or CDDP compared to untreated 
controls consistent with induction of autophagy.  
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 While autophagy induction was evidenced by changes in autophagy proteins for 
CCH-OS-D cells treated with either DOX or CDDP, autophagy induction in LM7 cells as 
evaluated by Western blot was only modest at best. Autophagy induction appeared to be 
greater at later time points and higher doses of DOX in LM7, however additional studies 
are needed to validate these findings and optimize conditions for chemotherapy-induced 
autophagy with DOX in LM7 cells. We have previously correlated the findings of 
Western blot analysis for autophagy induction in LM7 and CCH-OS-D cell lines treated 
with GCB and 9-NC by both acridine orange staining for AVOs and electron microscopy. 
These additional assays would allow further evaluation of chemotherapy-induced 
autophagy in both cell lines following DOX or CDDP and may validate the findings on 
Western blot analysis. 
 
Chemotherapy-induced authophagy serves a dual role in osteosarcoma cells treated with 
doxorubicin or cisplatin 
The effect of autophagy inhibition can give insights into the role of 
chemotherapy-induced autophagy. When chemotherapy induces cytoprotective 
autophagy and chemoresistance, the addition of autophagy inhibition to chemotherapy 
results in increased chemosensitivity and decreased cell viability. Conversely, if 
autophagy serves a cytotoxic role and is a mechanism of cell death, blocking autophagy 
in addition to chemotherapy is expected to result in increased cell viability. To determine 
the role of chemotherapy-induced autophagy in LM7 and CCH-OS-D treated with DOX 
and CDDP as either cytoprotective or cytotoxic, viability studies were completed using 
chemotherapy alone or in combination with the autophagy inhibitor HCQ. 
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LM7 and CCH-OS-D cells were treated with HCQ, DOX alone, CDDP alone, or 
combination DOX+HCQ pretreatment or CDDP+HCQ pretreatment and collected at 48 
and 72 hours. Viability was assessed using trypan blue exclusion via ViCell and 
compared to untreated controls at each time point. All conditions were conducted with 3 
replicates and experiments were repeated 3 times. Combining HCQ with either DOX (0.2 
ug/mL) or CDDP (20 uM) resulted in a trend towards decreased cell viability for LM7 
(Figures 20 and 21, respectively). While this effect was not statistically significant, this 
may be in part due to inadequate autophagy induction at the specified dose and time point 
of analysis.  
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Figure 20. Pharmacologic inhibition of autophagy prior to DOX results in a trend 
towards increased chemosensitivity in LM7 cells. Cells were treated with HCQ (20 uM), 
DOX (0.2 ug/mL), or pretreated with HCQ for 20 minutes prior to DOX treatment for 48 
and 72 hours. Cell viability was measured by trypan blue exclusion assay.  
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Figure 21. Pharmacologic inhibition of autophagy prior to CDDP results in a trend 
towards increased chemosensitivity in LM7 cells. Cells were treated with HCQ (20 uM), 
CDDP (20 uM), or pretreated with HCQ for 20 minutes prior to CDDP treatment for 24, 
48, and 72 hours. Cell viability was measured by trypan blue exclusion assay. 
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 Viability studies in LM7 were repeated with higher doses of DOX (1 ug/mL) and 
CDDP (40 uM) alone or in combination with HCQ for 48 and 72 hours. There were no 
significant differences in viability at 48 hours amongst the treatment groups (data not 
shown). However, at 72 hours combining HCQ with DOX resulted in a trend toward 
decreased viability (Figure 22, DOX vs DOX+HCQ p=0.094); combining HCQ with 
CDDP also decreased viability (Figure 23, CDDP vs CDDP+HCQ p=0.022). These 
findings support a cytoprotective role for autophagy in LM7 cells treated with DOX or 
CDDP.  
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Figure 22. Pharmacologic inhibition of autophagy prior to higher doses of DOX results 
in a trend towards increased chemosensitivity in LM7 cells at 72 hours. Cells were 
treated with hydroxychloroquine (CQ), DOX (1ug/mL), or pretreated with CQ for 20 
minutes prior to DOX treatment for 72 hours. Cell viability was measured by trypan blue 
exclusion assay. There was no difference in viability between untreated controls and 
HCQ alone. Pretreatment with HCQ prior to DOX resulted in a trend towards decreased 
viability as compared to DOX alone (p=0.094). 
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Figure 23. Pharmacologic inhibition of autophagy prior to higher doses of CDDP results 
in increased chemosensitivity in LM7 cells. Cells were treated with hydroxychloroquine 
(CQ), CDDP (40 uM), or pretreated with HCQ for 20 minutes prior to CDDP treatment 
for 72 hours. Cell viability was measured by trypan blue exclusion assay. There was no 
difference in viability between untreated controls and HCQ alone. Pretreatment with 
HCQ prior to CDDP resulted in decreased cell viability as compared to CDDP alone 
(p=0.022). 
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Conversely, the pretreatment with HCQ prior to DOX in CCH-OS-D resulted in 
increased cell viability at 48 and 72 hours (Figure 24). Combining in HCQ with CDDP in 
CCHOSD cells resulted in no change in viability (Figure 25). Notably, treatment with 
CDDP alone resulted in significant cytotoxicity at both 48 and 72 hours in CCH-OS-D 
cells which may have limited the apparent effect adding the autophagy inhibitor HCQ. 
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Figure 24. Pharmacologic inhibition of autophagy prior to DOX results in decreased  
chemosensitivity in CCH-OS-D cells. Cells were treated with HCQ (20 uM), DOX (0.2 
ug/mL), or pretreated with HCQ for 20 minutes prior to DOX treatment for 48 and 72 
hours. Cell viability was measured by trypan blue exclusion assay. Pretreatment with 
HCQ prior to DOX resulted in increased cell viability as compared to DOX alone 
(p<0.001). 
 
 
*** *** 
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Figure 25. Pharmacologic inhibition of autophagy prior to CDDP does not alter  
chemosensitivity in CCH-OS-D cells. Cells were treated with HCQ (20 uM), CDDP (20 
uM), or pretreated with HCQ for 20 minutes prior to CDDP treatment for 48 and 72 
hours. Cell viability was measured by trypan blue exclusion assay. CDDP alone 
significantly decreased viability at both 48 and 72 hours; pretreatment with HCQ did not 
change viability at either time point. 
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Taken together, these findings support a dual role for chemotherapy-induced 
autophagy in osteosarcoma. The data with LM7 cells are in line with other studies that 
have firmly established the induction of cytoprotective autophagy with either DOX or 
CDDP in osteosarcoma cell lines. We found that in CCH-OS-D cells autophagy 
inhibition with HCQ prior to DOX treatment resulted in increased cell viability 
suggesting a cytotoxic role for autophagy in this context. This presents a valuable model 
system for evaluating the mechanisms of cytoprotective vs cytotoxic autophagy and for 
exploring the effects of autophagy modulation. Additional studies are needed to confirm 
these findings. While we have shown this duality in other osteosarcoma cell lines and 
with various chemotherapeutic agents, these findings would benefit greatly from 
validation in vivo.  
 
Post-treatment phosphorylated HSP27 expression correlates with the role of autophagy 
and effect of autophagy inhibition in osteosarcoma cells  
Previously, we identified that treatment of LM7 and CCH-OS-D cells with GCB 
resulted in opposing effects of autophagy. A human phosphokinase array was used to 
identify differentially expressed proteins and phosphoproteins that could serve as 
potential biomarkers and to gain mechanistic insights into the opposing roles of 
chemotherapy-induced autophagy. Post-treatment expression of pHSP27 correlated with 
the role of autophagy and effect of autophagy inhibition independent of cell line, species 
of origin (murine or human osteosarcoma), or chemotherapeutic agent. An increase in 
pHSP27 (but not total HSP27) following chemotherapy correlated with a cytoprotective 
role for autophagy and therefore was associated with a benefit to adding HCQ to 
chemotherapy. Decreased expression of pHSP27 following treatment correlated with 
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cytotoxic autophagy and alternate cell death. In this setting, the addition of HCQ was 
associated with increased cell viability. These findings may have important biomarker 
implications for the treatment of patients with osteosarcoma with autophagy inhibitors. 
We therefore sought to validate these findings in osteosarcoma cells following treatment 
with standard chemotherapy, DOX and CDDP. 
LM7 and CCHOSD cells were treated with DOX or CDDP for 48 hours; 
untreated cells were used as a control. Phosphoprotein expression was determined using 
the human phosphokinase antibody array kit (R&D Systems) and analyzed by 
densitometry. Multiple phosphoproteins demonstrated changes in expression following 
treatment with chemotherapy (data not shown).  Specifically, pHSP27 (s78/82) was 
decreased in CCHOSD cells following DOX or CDDP and increased in LM7 with both 
agents (Figure 26). In comparison, heat shock protein 60 (HSP60) was increased with 
DOXO in both cells lines and relatively unchanged following CDDP treatment.  
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Figure 26. Post-treatment expression of phosphorylated HSP27 varies by osteosarcoma 
cell line. LM7 and CCH-OS-D cells were treated with DOX (0.2ug/mL) or CDDP (20 
uM) for 48 hours. Proteins were detected using a human phosphokinase antibody array 
kit (R&D Systems). DOX and CDDP resulted in increased expression of pHSP27 (red 
boxes, left; relative densitometry, right) in LM7 cells as compared to untreated controls. 
Conversely, pHSP27 expression was decreased in CCH-OS-D treated with DOX or 
CDDP.  HSP60 expression is shown for comparison. Additional 
proteins/phosphoproteins not shown. 
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 These findings are consistent with prior work from our lab, demonstrating 
induction of pHSP27 following treatment correlated with a cytprotective role of 
autophagy in osteosarcoma. However, the limited number of replicates and 
semiquantitative approach did not allow for evaluating the statistical significance of these 
findings. Functional proteomic profiling by reverse phase protein lysate array is currently 
underway for both cell lines treated with DOX, CDDP, and GCB to validate these 
findings. This platform includes a panel of >290 proteins and phosphoproteins including 
HSP72, pHSP27, HMGB1, as well as other key autophagy-related and apoptotic pathway 
proteins. These studies will allow for further exploration of specific pathways associated 
with cytotoxic vs cytoprotective autophagy in osteosarcoma. 
 
Summary of in vitro Studies 
Both doxorubicin and cisplatin are able to induce autophagy in LM7 and CCH-
OS-D cell lines, however the dose and time point for maximal chemotherapy-induced 
autophagy or increased autophagic flux may vary depending on the cell line or 
chemotherapeutic agent used. Further, autophagy inhibition can result in either increased 
chemosensitivity and decreased viability (in the case of doxorubicin or cisplatin in LM7) 
or alternatively, can reduce chemosensitivity and increase viability (for doxorubicin in 
CCH-OS-D). These findings imply a dual role for chemotherapy-induced autophagy in 
osteosarcoma, either as a cytoprotective mechanism promoting cell survival or cytotoxic 
leading to cell death. Finally, we demonstrated that the post-treatment expression of 
pHSP27 correlated with the role of autophagy and effect of autophagy inhibition. In LM7 
cells, doxorubicin and cisplatin result in increased expression of pHSP27 and induction 
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of cytoprotective autophagy. In CCH-OS-D where autophagy appears to be cytotoxic, 
pHSP27 expression decreases following doxorubicin exposure. These findings are 
summarized in Table 21.  
 
 
 
Table 21. Summary of in vitro studies.    
LM7 CCHOSD
Doxorubicin Cisplatin Doxorubicin Cisplatin
Autophagy Varying degrees of autophagy induction in both cell lines with both agents
Effect of autophagy 
inhibition
Decreased viability Decreased viability Increased viability No change in 
viability
Post-treatment 
pHSP27 expression
Increased Increased Decrease Decrease
Proposed Role of 
Autophagy
Cell survival Cell survival Cell death No effect
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IV. Discussion 
The paradoxical role of autophagy in cancer has been well described, however the 
key determinants of autophagy as either a mechanism of chemoresistance or promoting 
cancer cell death have not been defined. Defining the role of autophagy in a specific 
context and identifying potential biomarkers that could therefore predict benefit (or 
potentially harm) for combining autophagy inhibitors with cytotoxic chemotherapy is 
needed. In this project, we sought to understand the role and prognostic significance of 
chemotherapy-induced autophagy in osteosarcoma patients treated with standard MAP 
chemotherapy as well as in osteosarcoma cell lines and to correlate these findings with 
expression of HSP27/pHSP27.  
First, we show that both cytoplasmic LC3B puncta and HSP27 expression are 
relevant prognostic biomarkers in patients with localized osteosarcoma. Patients that lack 
LC3B+ puncta (<10% of cells) at resection following preoperative chemotherapy have a 
poor prognosis, as did patients who expressed HSP27 (>10% of cells). By combining 
these 2 markers at resection, we were able to identify a favorable risk group (HSP27-
/LC3B+) and those with particularly poor risk (HSP27+/LC3B-) with standard therapy. 
These markers may be valuable in risk stratification and support the development of 
clinical trials targeting either HSP27 or modulating autophagy in osteosarcoma.   
Although several studies have examined the role of chemotherapy-induced 
autophagy in osteosarcoma cell lines, to our knowledge, the presence and prognostic 
significance of autophagy markers such as LC3B has not been previously reported in 
osteosarcoma patients. While the majority of preclinical data suggest that chemotherapy-
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induced autophagy is a mechanism of chemoresistance to standard MAP chemotherapy in 
osteosarcoma,65, 70, 101 and the expression LC3B has been shown to be a poor prognostic 
marker in multiple other cancer types,102 we found the opposite. The presence of LC3B 
puncta following chemotherapy was a positive prognostic marker in osteosarcoma. One 
large study of >1600 breast cancer patients similarly showed the presence of cytoplasmic 
LC3B to be a favorable prognostic marker following adjuvant chemotherapy.56 Using a 
similar methodology to evaluate LC3B puncta in tumor cells and the same >10% cutoff, 
Laoire et al demonstrated that the combined positivity to LC3B+ puncta and presence of 
nuclear HMGB1 was associated with prolonged metastasis-free and breast cancer specific 
survival. Additionally, the authors showed that LC3B+ puncta correlated with a reduction 
in SQSTM1/p62, suggesting that a high percentage of LC3B+ puncta reflects increased 
autophagic flux.  
In our study, a limited number of patients demonstrated LC3B puncta on pre-
treatment specimens suggestive of basal autophagy in a subset of primary osteosarcoma. 
However, this finding was not associated with relapse-free survival, overall survival, or 
pathologic treatment response. Overall, the proportion of osteosarcoma with LC3B+ 
puncta was significantly higher in post-treatment specimens, though the majority of these 
specimens were not paired. In the nine patients with paired pre-/post-chemotherapy 
specimens who were initially negative for cytoplasmic LC3Bpuncta, >50% were positive 
following chemotherapy. Taken together, these findings suggest that standard 
chemotherapy can induce autophagy in a subset of patients with osteosarcoma and that 
chemotherapy-induced autophagy may be favorable in the primary treatment of 
osteosarcoma. The presence of LC3B+ either prior to treatment or at resection did not 
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correlate with percent tumor necrosis nor was it significantly associated with a “good” 
pathologic response, suggesting that LC3B+ is an independent prognostic biomarker 
rather than a surrogate marker for pathologic treatment response. Even amongst the 
subset of poor responders, patients lacking LC3B following chemotherapy had a trend 
towards inferior overall survival. 
The association of post-treatment LC3B puncta and favorable outcomes suggests 
that chemotherapy-induced autophagy following MAP may serve as mechanism of 
alternate cell death as opposed to chemoresistance in primary osteosarcoma. Rather than 
combining chemotherapy with autophagy inhibitors,2, 66, 67, 69, 71 strategies that induce 
autophagy such as mTOR inhibition103, 104 or other agents58 that are currently being 
explored in osteosarcoma may prove beneficial when added to primary therapy. The 
implications for targeting autophagy (either promoting or inhibiting it) in 
recurrent/metastatic osteosarcoma remain unclear. LC3B puncta was observed in the 
majority of metastasis specimens (67%). Further, in a limited number of metachronous 
biopsy-metastasis and resection-metastasis pairs, LC3B became positive in the majority 
of patients who were initially scored as negative. Given the conflicting data regarding the 
association of LC3B puncta with improved relapse free and overall survival but its 
increased occurrence in osteosarcoma metastasis, it would be premature to conclude 
whether autophagy, as evidenced by LC3B, is a driver of osteosarcoma metastasis and 
therefore should be inhibited. Additional mechanistic studies are needed.  
In regard to HSP27, our study is in agreement with prior studies that have shown 
overexpression of HSP27+ at biopsy as an independent poor prognostic factor.89, 90 
However, in these 2 small series the proportion of HSP27+ tumors (>10% of tumor cells) 
  
98 
was much lower both at biopsy (22-24%) and resection (33-37%) as compared to our 
finding (85% and 52%, respectively). While Uozaki et al found an association between 
HSP27+ at resection and poor response among 19 patients evaluated, HSP27+ did not 
correlate with pathologic treatment response in our analysis. Although not a predictive 
biomarker of pathologic response, the negative prognostic implications of HSP27 
overexpression at diagnosis support strategies combining HSP27 inhibition with primary 
MAP chemotherapy. Several preclinical studies support the rationale for targeting HSP27 
in osteosarcoma.105-107 
We examined the combination of HSP27 and LC3B in osteosarcoma patient 
samples based upon preclinical data suggesting an association between HSP27, pHSP27, 
and autophagy. The ER stress response/ubiquitin-proteosome system, mitochondrial 
autophagy (mitophagy), and the Akt/mTOR pathway have been proposed as mechanisms 
linking HSP27 and autophagy.108, 109 In addition, HMGB1 which has been shown to 
promote drug resistance in osteosarcoma cell lines by inducing autophagy, regulates the 
expression HSP27. 108  
In osteosarcoma cell lines, both doxorubicin and cisplatin can induce autophagy. 
However, this may lead to either cell survival or cell death and therefore opposing effects 
of autophagy inhibition. We previously demonstrated that increased expression of 
pHSP27 following chemotherapy exposure was associated with cytoprotecitve autophagy 
and chemoresistance.73 Here we found consistent findings when LM7 and CCH-OS-D 
cells were treated with either doxorubicin or cisplatin. Notably, however, the association 
between the role of autophagy, effect of autophagy inhibition, and total HSP27 in 
osteosarcoma cell lines has been inconsistent. We sought to evaluate pHSP27 in 
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osteosarcoma tumor specimens based upon the initial hypothesis but labeling was 
severely limited likely due to the decalcification protocols used in processing bone tumor 
specimens in FFPE tissue. We found no correlation between the LC3B puncta and 
HSP27+ in patient specimens.  
There are several limitations to the current study. In regard to the biomarker 
analysis, all samples were analyzed retrospectively from a single institution and there 
were a limited number of pretreatment biopsy specimens. This significantly limited the 
number of pre-treatment/post-treatment paired samples available for analysis and 
therefore limited our ability to specifically assess chemotherapy-induced autophagy. 
Further, based upon the initial hypothesis and cell line data, we sought to explore pre-
/post-treatment changes in HSP27 and pHSP27 expression (rather than absolute 
expression) in relation to autophagy markers. This analysis could not be conducted given 
the lack of paired samples and our inability to accurately measure pHSP27 in decalcified 
bone tumor specimens. Finally, autophagy was assessed by a single marker, LC3B 
puncta. The addition of other autophagy markers such as p62 to confirm the presence of 
autophagic flux or the autophagy-related DNA binding protein HMB1 to this analysis 
would serve to validate these findings and is currently underway.  
In regard to analysis of chemotherapy-induced autophagy in osteosarcoma cell 
lines, optimal conditions for autophagy induction with doxorubicin and cisplatin in LM7 
cells were not defined. While both agents were shown to induce some degree of 
autophagy, insufficient autophagy induction may limit the implications of the viability 
studies and post-treatment pHSP27 expression data. Finally, while we have demonstrated 
a correlation between the role of chemotherapy-induced autophagy and pHSP27 in 
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osteosarcoma cell lines, the functional significance and potential mechanistic basis of 
these findings have not been explored. 
This study adds to our prior work identifying a context-dependent dual role for 
chemotherapy-induced autophagy in osteosarcoma that is independent of cell line, 
species of origin, or chemotherapeutic agent. These findings establish a valuable model 
system to further evaluate the mechanisms underlying of cytotoxic vs. cytoprotective 
autophagy. While pHSP27 was initially identified as a differentially expressed protein 
that consistently correlates with the role of autophagy, its functional significance remains 
unclear. Future studies stemming from this project will undertake functional proteomic 
profiling by RPPA to identify additional proteins and key pathways associated with the 
opposing effects of autophagy as well as functional studies using shHSP27 knockdowns 
in LM7 and overexpression of HSP27 in CCH-OS-D cells to determine if HSP27 is 
indeed necessary for cytoprotective autophagy in osteosarcoma. Given that pHSP27 (but 
not total HSP27) correlates with the role of autophagy, identifying the specific kinases 
involved in phosphorylating HSP27 in each context may give additional mechanistic 
insights. Finally, in vivo studies combining autophagy inhibitors with chemotherapy in 
the treatment of osteosarcoma will be a key step in translating these findings to the clinic. 
Independent of their potential mechanistic link, HSP27 and LC3B can be 
considered as independent biomarkers in osteosarcoma; if analyzed together they allow 
for improved risk stratification for localized osteosarcoma patients following 
preoperative chemotherapy. One of the limitations of this approach, however, is awaiting 
evaluation of these markers at resection ~12 weeks into therapy. Predictive biomarkers of 
response to conventional MAP chemotherapy are needed. Such markers would allow for 
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modification or intensification of preoperative therapy for poor risk patients in a window 
trial paradigm that would allow for paired biomarker assessment. Prospective analysis of 
paired-samples may be beneficial in validating HSP27 and LC3B puncta as prognostic 
and potentially as predictive biomarkers in osteosarcoma. This would justify the addition 
of HSP27 targeted therapies or agents that promote autophagy to standard chemotherapy 
in poor risk patients.  
 
V. Conclusions  
 While previously thought to be primarily a mechanism of chemoresistance, 
chemotherapy-induced autophagy can serve a dual role in osteosarcoma. Autophagy 
following standard chemotherapy as evidenced by the presence of LCB puncta in 
osteosarcoma tumor cells is associated with favorable outcomes. Conversely, 
overexpression of HSP27 is a negative prognostic marker prior to treatment or following 
preoperative chemotherapy. When evaluated together, the combination of LC3B-
/HSP27+ identifies particularly poor risk patients following preoperative chemotherapy. 
These findings not only establish HSP27 and LC3B as prognostic biomarkers in 
osteosarcoma but serve as a rationale for future studies targeting either HSP27 or 
modulating autophagy in osteosarcoma treatment. 
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